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Introduction. 
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Chapter one. 
Introduction. 
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1.1 The hepatitis B virus:history. 
An outbreak of parenterally transmitted hepatitis was probably 
first recorded in 1885 by Lurman who reported the occurrence of 
jaundice among personnel of a Bremen factory after revaccination 
against smallpox.Of 1289 individuals vaccinated in one day,191 
developed jaundice 2 to 8 months after administration of 
glycerinated human lymph preparations.The illness usually began 
with fatigue,anorexia and gastrointestinal complaints followed by 
jaundice and often pruritus;it generally lasted a total of 4 to 6 
weeks.Personnel vaccinated on another day with another vaccine 
preparation as well as those who left the job before 
revaccination were not affected,Comparison of the water supply, 
domicile,alcohol abuse and vaccine exposure indicated the latter 
as the probable cause of the outbreak (1,2,3).In 1945 MacCallum 
postulated that,on the basis of differences in incubation period 
and mode of transmission,two different agents cause hepatitis: 
hepatitis A and hepatitis B.He was not able to isolate the 
infectious agents (4).In 1967 Krugman and Giles confirmed the 
existence of two types of hepatitis:one with a short and one with 
a long incubation period (5).In 1965 Blumberg had already 
discovered an antigen in the serum of an Australian aboriginal 
which he called 'Australia antigen' (6).In 1968 Prince identified 
an antigen in the serum of patients with post-transfusion 
hepatitis,an antigen which he called SH antigen (7).The antigens 
discovered by Blumberg and Prince were found to be identical and 
represent the hepatitis B surface antigen.Between 1968 and 1973 
the other principal viral antigens <HBeAg,HBcAg) and their 
antibodies were identified (8,9).The electron microscopy features 
of the virus were described by Dane in 1970.In the blood of 
infected patients the large complete virus particle (diameter 42 
nm),small 22 nm spherical surface antigen particles and tubular 
forms (length 100 nm,diameter 22 nm) were found (10).Infection 
with the hepatitis B virus is characterized not only by 
production of infectious complete virus particles (Dane 
particles) but also by an enhanced production of incomplete 
viral particles made up entirely of HBsAg without HBcAg,DNA-
polymerase activity or HBV-DNA. 
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fig l.Schematic representation of the hepatitis B virus.The outer 
shell contains the pre-Sl,pre-S2 and surface antigens;a core 
particle contains the associated antigens HBeAg and HBcAg, 
nucleus-associated enzyme DNA-polymerase and partly double 
stranded circular DNA (partly from Neurath). 
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1.2 The hepatitis B virus. 
Hepatitis B virus is a DNA virus that belongs to a family of 
viruses called hepadna viruses (11 1 12).This family includes the 
woodchuck hepatitis virus 1 ground squirrel hepatitis virus 1 tree 
squirrel hepatitis virus and Peking duck hepatitis virus (13 1 14 1 
l5 1 16).Hepadna viruses are hepatotropic and tend to cause chronic 
infections;some of them have been associated with the development 
of hepatocellular carcinoma.HBV can cause infections in humans 
and certain non-human primates (chimpanzee and gibbon).The animal 
viruses do not appear to be infectious in man (17). 
The stucture of HBV is shown in figure l.It has an outer envelope 
composed of three related proteins:hepatitis B surface antigen 
(HBsAg:Australia antigen) 1 pre-Sl and pre-S2.Compared with HBsAg 
the pre-Sl and pre-S2 proteins are preferentially incorporated 
into the complete viral particl-e.All three forms of HBsAg (HBsAg 1 
pre-Sl 1 pre-S2) can become glycosylated.Protein analysis of HBsAg 
in serum can therefore yield HBsAg in six different sizes (18). 
The inner component of the infectious virion contains the core 
antigen (HBcAg:core antigen).Inside the core particle is a single 
molecule of circular 1 partially double-stranded DNA and an 
endogenous DNA-polymerase which also possesses reverse 
transcriptase activity.A third viral antigen associated with HBV 
is the hepatitis B 'e' antigen (HBeAg).HBeAg is a soluble protein 
closely related to core antigen.Disruption of core particles by 
detergents or proteolytic enzymes releases HBeAg reactivity.The 
presence of HBeAg in blood is associated with high levels of 
viral replication (19).A fourth viral antigen is the x-protein: 
the exact function of this polypeptide is still unknown.The 
antigens HBsAg 1 pre-Sl 1 pre-S2 1 HBcAg 1 HBeAg 1 HBxAg all can induce a 
specific antibody response 1 although the x-protein is not found 
in hepatitis B particles nor in any other form in blood. 
The HBV genome is the smallest of any of the viruses known to 
infect man.The DNA molecule contains partially double-stranded 
circular DNA 1 which is 3200 base pairs in length.A striking 
feature of the hepatitis B virus is the presence of overlapping 
gene sequences which enables the virus to produce more unique 
protein per genome unit than other viruses (20). 
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1.3 Chronic hepatitis B:impact on public health. 
On the basis of longitudinal studies of patients with hepatitis 
B,chronic hepatitis B has been defined as persistence of 
hepatitis B surface antigen i~ the circulation for more than six 
months.The number of HBsAg-positive patients worldwide is 
estimated to be 200 million,25 % of whom will die as a result of 
a liver-related affliction (2l).Primary hepatocellular carcinoma 
is one of the ten most common carcinomas in the world with an 
estimated yearly incidence of 250,000 cases (22).HBsAg-positive 
patients run an increased risk of developing hepatocellular 
carcinoma whereby the development of cirrhosis is an independent 
risk factor (21,23). 
1.4 Chronic hepatitis B:natural history. 
The natural history of the infection can be considered to consist 
of three phases (24): 
l.An initial period of high infectivity accompanied by various 
degrees of inflammatory activity in the liver.Serum AST levels 
are elevated and HBeAg,HBV-DNA and DNA-polymerase are present in 
the serum.In liver tissue HBcAg and HBV-DNA can be found.This 
period lasts for several years <fig 2,left panel). 
2.A transitional phase during which viral replication is reduced, 
HBeAg and often HBV-DNA are lost and increased lobular 
inflammation is seen in the liver.The loss of HBeAg is often 
accompanied by a flare in hepatitis activity which can cause 
severe liver damage if prolonged (25) <fig 2,right panel). 
3.A long-term phase of low infectivity with resolution of liver 
inflammation and detectable hepatitis B e antibody.Subsequently 
HBsAg may be lost.In phase 3 reactivation of HBV infection may 
occur with reappearance of replication markers (fig 2,right 
panel) (26).The incidence of reactivation may be higher for those 
with acquired immunodeficiency. 
These complex aspects of the disease have rendered the 
differentiation between the healthy HBsAg carrier state and 
chronic type B hepatitis with the subcategories chronic 
persistent and chronic active hepatitis outdated <27). 
Classification of chronic type B hepatitis is now based on the 
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presence or absence of HBV replication and liver cell 
inflammation.HBV replication can be assessed in serum by 
measuring HBV-DNA,DNA-polymerase activity or HBe-antigen and in 
the liver by immunologic detection of HBc-antigen.Routine 
measurement of HBV replication is most easily done by measuring 
HBeAg in serum and HBcAg in liver because of the general 
availability of these tests.Liver cell inflammation can be 
assessed by serum aminotransferase activity (AST).HBV replication 
is usually associated with an elevated AST and absence of HBV 
replication with normal AST levels (25,28,29).An elevated AST 
together with a negative HBeAg test points to low-level HBV 
replication <liver HBcAg positive,serum HBV-DNA positive) or to 
concomitant disease such as hepatitis D infection (delta agent), 
hepatocellular carcinoma,autoimmune reactivity,alcoholism,drug 
toxicity,schistosomiasis,non-A non-B hepatitis or metabolic 
disease (30,31). 
In general chronic hepatitis B can thus be classified as: 
l.HBeAg-positive chronic hepatitis B (CHBe+). 
2.HBeAg-negative,AST positive chronic hepatitis B (CHBe-/AST+). 
3.HBeAg-negative,AST negative chronic hepatitis B <CHBe-/AST-). 
HBeAg-positive chronic hepatitis B. 
Chronic HBeAg-positive hepatitis,which is characterized by active 
viral replication,is usually associated with symptoms and liver 
cell inflammation.The rate of spontaneous seroconversion from 
HBe-positive to anti-HBe positive has been reported to vary 
between about 5 % and 15 % per annum. Seroconversion from HBsAg+ 
to HBsAg- can follow several months to several years later in 
10-20% of these patients.In the vast majority of patients HBe-
seroconversion is accompanied by clinical,biochemical and 
histological improvement.However 5 % of patients show continuing 
disease activity with persistent viral replication,as indicated 
by the presence of HBV-DNA.The 5-year mortality rate can be less 
than 10% (32,33). 
HBeAg-negative,AST positive chronic hepatitis B. 
Patients with chronic HBeAg-negative hepatitis and an elevated 
serum aminotransferase activity form a heterogeneous group with 
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fig 2.Transition from the replicative phase (left panel) to the 
non-replicative phase of chronic type B hepatitis <right panel) 
with eventual loss of HBeAg and seroconversion to anti-HBe. 
Persistence of serum HBV-DNA is associated with progressive liver 
disease.HBe-negative,AST-positive chronic liver disease can be 
associated with superinfection with the delta agent. 
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either ongoing HBV replication or concomitant disease such as 
hepatitis D infection <delta agent),hepatocellular carcinoma, 
autoimmune reactivity,alcoholism,drug toxicity,schistosomiasis, 
non-A non-B hepatitis or metabolic disease.The natural history 
will vary according to the aetiology.HBs-seroconversion and HBe-
reactivation may be 5-10 times more common than in HBeAg-
negative,AST negative chronic hepatitis B.The 5-year mortality 
rate,which is markedly affected by the characteristics of the 
patients at diagnosis (asymptomatic chronic hepatitis B detected 
by screening or symptomatic decompensated cirrhosis),is highest 
(20-30%) for this category of patients with chronic hepatitis B 
(31,34). 
HBeAg-negative,AST negative chronic hepatitis B. 
Chronic HBe-negative hepatitis with normal serum aminotransferase 
activity usually develops without symptoms,liver cell 
inflammation and active viral replication.HBs-seroconversion 
occurs in approximately 1 % per year.HBe-reactivation is low,but 
elevated aminotransferase activity has been observed in 5-15% of 
cases.Mortality is low (32,35,36). 
Prevalence of the 3 types of chronic hepatitis B. 
Chronic HBeAg-positive hepatitis usually comprises about 15 % of 
all cases of chronic hepatitis B,whereas HBeAg-negative,AST 
negative chronic hepatitis B accounts for about 60 % and HBeAg-
negative,AST positive chronic hepatitis B about 25%.The 
prevalence of the three types of chronic hepatitis B may differ 
in various regions of the world (33,36,37,38). 
1.5 Chronic hepatitis B:goals and strategies for treatment. 
The goals of treatment are to alleviate symptoms,lower 
infectivity,prevent cirrhosis and minimize mortality due to 
liver failure and hepatocellular carcinoma.Strategies for therapy 
are required for chronic HBeAg-positive hepatitis and HBeAg-
negative,AST positive chronic hepatitis B;no therapy is indicated 
for HBeAg-negative,AST negative chronic hepatitis B. 
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Treatment of HBeAg-positive chronic hepatitis B infection. 
The relationship between active HBV replication and histological 
hepatic damage has been well documented;several studies have now 
shown that disappearance of HBeAg from the serum and the 
development of anti-HBe lead to low infectivity as well as 
clinical,biochemical and histological remission in the majority 
of individuals (25,28,29).Disease progression will then stop; 
prevention of cirrhosis may also decrease the incidence of 
hepatocellular carcinoma. 
Treatment of HBeAg-negative/AST positive chronic hepatitis B. 
In HBeAg-negative,AST positive chronic hepatitis B suppression of 
liver cell inflammation appears to be crucial.Elimination of 
aetiological factors (HBV,HDV,alcohol,drugs,schistosomiasis) 
should be the initial therapeutic approach.Antiviral agents 
could be beneficial for a subgroup with circulating virus DNA 
despite the absence of HBeAg (30,33). 
1.6 Objectives of the study. 
l.To review the main current therapeutic approaches - with a 
single agent - to HBeAg-positive chronic hepatitis B as they have 
been reported in literature (chapter 2). 
2.To evaluate the inhibitory effect on viral replication as well 
as the efficacy of acyclovir, descyclovir and alpha-interferon 
alone or as combination therapy in chronic HBV infection 
(chapters 3,4,5,6,7,9). 
3.To study the mechanisms of a combination therapy-induced 
transition from the state of active viral replication to the 
state of virus latency in more detail (chapter 9).In particular 
we investigated whether the level of serum beta-2 microglobulin 
either before or during treatment can be used to predict the 
response to antiviral combination therapy (chapter 8). 
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Chapter 2. 
2.1 Introduction. 
The goals of the treatment of patients with chronic HBV infection 
are to alleviate symptoms,lower infectivity,prevent cirrhosis and 
minimize mortality due to liver failure and hepatocellular 
carcinoma.This chapter will focus on patients in the HBe-positive 
phase of the disease.Active viral replication in these patients 
is reflected by the presence of HBeAg,DNA-polymerase activity and 
HBV-DNA in the serum.Therapy is directed towards inhibition of 
viral replication,as reflected by the loss of the antigen related 
to active viral replication (HBe-seroconversion) and elimination 
of HBV-DNA from the serum.In a complete therapeutic response 
production of incomplete viral particles will cease (HBs-
seroconversion) and antibodies will develop. 
Targets for therapy in chronic HBe positive hepatitis. 
The host's immune system is responsible for clearance of the 
virus,which is more likely to occur in patients with low levels 
of viral replication (1,2).Presentation of viral proteins to the 
immune system and various steps in the viral replication cycle 
are targets for antiviral therapy (fig 1). 
The major therapeutic approaches to the patient with chronic 
hepatitis B are summarized in table !.Although other methods of 
treatment have been described,those listed in table 1 have been 
subjected to at least two randomized controlled trials.I will 
discuss the results of the trials in detail in this chapter.New 
developments in antiviral combination therapy will be considered 
in chapter 10. 
Table 1. Therapeutic approaches to chronic hepatitis B. 
!.Synthetic antivirals. 
Acyclovir 
Adenine Arabinoside (ARA-A,ARA-AMP) 
2.Immune modulation. 
Alpha-interferon 
Corticosteroid withdrawal 
3.New developments in antiviral therapy. 
Combination therapy 
Drug targetting 
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fig l.Possible targets for antiviral therapy. 
A.Presentation of viral proteins to the immune system 
B.Viral replication cycle:viral cell entrance 
:viral DNA-polymerase activity 
:cellular RNA-polymerase activity 
:viral reverse transcriptase activity 
:viral protein synthesis 
:viral assembly 
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Inhibition of reverse transcription 
Immune modulatory therapy 
Possible modes of action. 
The main action of synthetic antivirals is inhibition of both 
chain elongation and viral DNA-polymerase activity.Depending on 
the selectivity of the action between host and virus,synthetic 
antivirals may also be immunosuppressive.Interferons have a 
direct antiviral action as well as an immune modulatory 
function.Expression of antigens of the MHC class I in combination 
with viral antigens on the hepatocyte surface leads to cytotoxic 
immune reactions and elimination of infected cells.Increased 
expression in combination with inhibition of viral replication is 
induced by interferon therapy and also plays an important role in 
the immunologic rebound after corticosteroid withdrawal (3). 
Interferons may inhibit virus entry as well as subsequent events 
in the replication cycle within the target cell (4). 
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2.2 Interferon. 
l.The agent. 
In 1957 Isaacs and Lindeman discovered interferon,an agent of 
viral interference.Interferon is a protein which is released by 
cells exposed to a virus and enables other cells to resist viral 
infection (l).It has become clear that the interferons form a 
large family of species-specific proteins that are produced by 
virus-infected cells in vivo and in vitro and are important in 
the natural control of virus infections (2).In addition 
interferons can be induced by various other stimuli,including 
other cytokines.Three main types of interferon have now been 
recognized:interferon-alpha,beta and gamma (3).Alpha-interferon 
is produced by B-lymphocytes and monocytes,beta-interferon by 
fibroblasts and gamma-interferon by T-lymphocytes (4).Because of 
the wide clinical application of alpha-interferon compared to 
interferon-beta and gamma,I will concentrate on the former.The 
prototype of human alpha-interferon was leucocyte interferon,the 
product made when human buffy coat cells are stimulated with 
Sendai virus (5).Further analysis has shown that preparations of 
human leucocyte interferon are not homogeneous.Recombinant DNA 
technology has confirmed that a number of genes each code for an 
individual subtype of interferon.There are at least 15,and 
probably more,of these subtypes which although chemically 
distinct exhibit closely related amino acid sequences (6) .In 
vitro each individual subtype differs from the others in its 
biological properties (7l.The particular mixture of alpha-
interferon subtypes depends on the conditions of manufacture and 
purification.Lymphoblastoid interferon,which consists of a 
mixture of alpha-interferon subtypes,is made by stimulating cells 
of the Namalwa cell line with Sendai virus.In our clinical 
studies we used lymphoblastoid alpha-interferon (Wellferon). 
Individual subtypes of alpha-interferon can be produced in 
significant quantities by recombinant DNA technology.Commercially 
available recombinant interferons contain alpha-2a (Roferon-A; 
Hoffman-La Roche),alpha-2b (Intron-A,Schering Corporation) or 
alpha-2c interferon (Boehringer).Biological activity of 
interferons is usually measured in terms of the antiviral effects 
in vitro.Depending on the particular interferon 10-100 pg. 
correspond to one unit of antiviral activity. 
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2.Mode of action. 
Interferons have a distinct antiviral and immunomodulatory 
action.Although there is an enormous amount of data on the 
isolated effects of interferon on cell systems 1 an overall 
understanding of the precise mode of action of interferon is 
lacking.I will discuss the effects of interferon in the normal 
host 1 followed by the effects of interferon in patients with 
chronic hepatitis B virus infection.Finally we will describe a 
hypothesis for the mode of action and the rationale behind the 
therapeutic use of interferon in patients with chronic hepatitis 
B. 
After an intramuscular or subcutaneous injection 1 absorption into 
the bloodstream is relatively quick and maximum blood levels are 
obtained 4-6 hours later.Clearance from the blood is rapid:after 
an intravenous injection 1 the initially high blood levels drop 
rapidly to about 10 % of the original value within 1 hour. 
Interferons are eliminated mainly by glomerular filtration 
followed by reabsorption by renal tubular cells and catabolism. 
They are active at extremely low concentrations (fmol/ml) (8). 
The antiviral response in cells is elicited by binding to the 
specific interferon receptor.Interferon-alpha and beta share this 
receptor while interferon-gamma has a separate receptor.The 
alpha-interferon receptor consists of two parts:a binding site 
and an activation site (9 1 10).After binding intracellular 
protective mechanisms are activated by a second messenger 1 not by 
the direct intracellular injection of interferon (11 1 12 1 13). 
Interferon stimulates the synthesis of intracellular protein 
kinase and the intracellular enzyme system 2' 1 5'-oligoadenylate 
synthetase/endonuclease.Activation of this latter system leads 
to the production of short oligonucleotides which 1 in the presence 
of ATP and double-stranded RNA 1 activate ribonucleases <fig 1.) 
(14).It has been suggested that the activation of these 
ribonucleases 1 which destroy viral messenger RNA and ribosomal 
RNA within infected cells 1 is the major mechanism by which 
interferons inhibit viral replication.The requirement of double-
stranded RNA or another activator is one explanation for the 
selective inhibition of protein synthesis in virus-infected 
cells.Activation of intracellular protein kinase initiates 
phosphorylation of an initiating factor essential for protein 
synthesis.After phosphorylation the initiating factor is 
inactive and protein synthesis is therefore inhibited (fig 1.) 
(15 1 16).However interferons may also inhibit other parts of the 
Interferon (X/j3 receptor 
1 
r- Second messenger 
Protein kinase inactive - active 
! 
Initiating factor active - inactive 
1 
Inhibition initiation 
protein synthesis 
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DsRNA 
others 
Interferon y receptor 
l 
2' 5' oligosynthetase inactive- active 
! 
2' 5' oligoadenylates synthesis 
Phosphodiesterase f- l 
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l 
l Degradation mANA; rRNA 
'""'"""" '""'" "'".,.' wllh ~''"M~ J'"""''" "'"'"~"' 
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fig 1. Induction of cellular enzyme systems by interferon and their inhibitory effect on 
protein synthesis. 
tv 
...., 
24 
Table 1. Mechanisms of interferon actions (partly from (18)). 
EFFECT 
Antiviral: 
Inhibition of virus entry into the 
cell 
Inhibition of virus uncoating 
Activation of cellular ribonucleases 
Inhibition of RNA translation 
Inhibition of viral assembly 
Immunomodulatory: 
Amplification of class I HLA 
display on virus-infected cells 
Activation of antigen-processing 
cells 
Augmentation of NK cells activity 
Increase in sensitivity of 
virus-infected cellls to 
cytotoxic T-cells attack 
Result 
Protects uninfected cells 
Protects uninfected cells 
Destroys viral mRNA 
Prevents production of 
viral components 
Prevents completion of 
viral replication 
Makes virus antigen on 
cell membrane more visible 
to antigen-processing 
cells 
Improved recognition of 
viral antigens 
Nonspecific killing of 
virus-infected cells 
Specific killing of virus 
-infected cells 
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viral replication cycle (table 1) (17,18). 
The interferon system in chronic viral hepatitis. 
Interferons possess several potent immunomodulatory 
characteristics which are important in viral clearance. 
Interferons amplify HLA class I antigen expression on the 
membranes of virus-infected cells (19,20).Activation of antigen-
processing cells which recognize viral-HLA antigen complexes on 
cell membranes is increased (2l).Studies of patients with chronic 
HBV infection suggest that the nucleocapsid antigens (HBe and 
HBc) are the important targets (22,23) .Cytotoxicity of T and 
K-lymphocytes is increased.Natural killer cell activity is 
enhanced by interferon,although conflicting results have been 
reported (24,25).Interferons also direct the cytotoxic 
T-lymphocyte response by decreasing the resistance of virus-
infected cells to such an attack,while increasing the threshold 
of uninfected cells against attack by the virus (26). 
In contrast to acute viral hepatitis, the endogenous interferon 
system does not seem to be stimulated during chronic viral 
hepatitis.Despite the presence of active viral replication serum 
interferon is not detectable in patients in the chronic phase of 
the disease (27).At the hepatocellular level there is evidence 
of abnormal activation of the hepatocytes by endogenous 
interferon:the expression of HLA class I antigens on hepatocyte 
membranes is not enhanced (28,29);cellular 2'5'-oligoadenylate 
synthetase activity exhibits only a minimal increase (27,30). 
Using monoclonal and polyclonal antibodies against alpha-2 
interferon in liver sections from patients with chronic HBV 
infection,it was shown that mononuclear cells and fibroblasts 
are positive in patients with chronic active hepatitis or 
cirrhosis.Alpha-2 interferon-positive cells were often found 
adjacent to hepatocytes that contain cytoplasmic core antigen 
associated with active viral replication.In vivo interferon 
production was demonstrated at the site of viral replication 
which implies local and not systemic regulatory mechanisms 
(31) .Peripheral blood mononuclear cells are not primed for 
interferon production (32,33).In vitro production of alpha and 
gamma-interferon by stimulated peripheral blood mononuclear 
cells from patients with chronic hepatitis was lower than that 
f6und for healthy controls,although there was considerable 
overlap <34). 
The interferon-induced enzyme 2' ,5'-oligoadenylate synthetase 
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reflects the level of in vivo activation of the interferon 
system.In patients with chronic active hepatitis B a lack of 
activation has been shown,whereas 50 % of asymptomatic HBsAg 
carriers and patients with chronic persistent hepatitis exhibit 
in vivo activation (30).This result was not confirmed in a recent 
report which showed normal levels of 2',5'-oligoadenylate 
synthetase in chronic HBV infection (35).These findings have led 
to the hypothesis that a defect in the ability to produce 
sufficient amounts of alpha-interferon during acute viral 
hepatitis may give rise to chronic infection (36) .However it is 
not known whether the defect in interferon production already 
exists before occurrence of the hepatitis infection or is a 
consequence of the infection itself.There are several 
contradictions in this hypothesis:if the basic defect is a lack 
of interferon production,activation of cytotoxic lymphocytes is 
not to be expected;moreover low levels of serum interferon may be 
attributable to insensitive test methodology or inaccurate timing 
of the test.Interferon production is reduced in vitro but there 
is considerable overlap with uninfected controls;moreover 
extrapolation of data from the in vitro to the in vivo situation 
is always dangerous.Defects that are measured in circulating 
lymphocytes do not necessarily reflect the activity of the 
interferon system in the liver because in situ interferon 
production has been shown in cells adjacent to cells with active 
viral replication.However it is possible that hepatitis viruses 
suppress interferon production,because at the cellular level a 
nucleotide homology exists between HBV and the sequences that 
regulate the interferon-induced antiviral system (37). 
Changes in the cellular response to interferon after hepatitis B 
virus infection have also been postulated.Recent transfection 
experiments have indicated that cells transfected with the 
hepatitis B genome are less sensitive to exogenous interferon 
(38).In patients with chronic hepatitis exogenous interferon 
induces the expression of HLA class I and beta-2 microglobulin 
and activates cytotoxic lymphocytes.However,interferon remains a 
moderately effective therapeutic agent in the majority of these 
cases,which might imply that the basic defect is not a lack of 
interferon;instead the low levels of interferon may be one of 
the sequela of the chronic viral infection.The rapid increase in 
ALAT levels after 8-12 weeks of exogenous interferon therapy, 
reflecting immunologic attack on the hepatocyte after the virus 
load has been reduced,is compatible with this finding (39,40,41). 
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3.Clinical trials. 
The fact that alpha-interferons exhibit a broad antiviral 
activity in combination with the observation of possible defects 
in interferon production in patients gave rise to clinical 
studies of interferon in chronic hepatitis B. 
Open studies of alpha-interferon. 
The first open studies on interferon therapy for chronic active 
hepatitis B infection were published in l976.The Stanford group 
reported on the use of Cantell (buffy coat) interferon in man. 
Four patients were treated with dosages ranging between 6,000 
and 170,000 units of interferon/kg bodyweight (specific activity 
500,000 units per mg protein) which resulted in a rapid and 
reproducible decline in HBsAg,HBcAg levels and DNA-polymerase 
activity.DNA-polymerase activity returned to initial levels when 
therapy was discontinued within 10 days or less.Prolonged therapy 
lasting several weeks produced a more permanent suppression of 
polymerase activity (42).At the same time the group from Leuven 
reported on the effects of fibroblast interferon in the 
chimpanzee and man.In the chimpanzee a rapid decrease in 
intrahepatic core expression was observed,indicating that 
replication of the hepatitis B virus is sensitive to interferon 
(43).These studies led to a number of small open studies aimed 
at defining the appropriate dose,tolerance and possible duration 
of therapy.Relatively low doses of alpha-interferon have the same 
antiviral effects as high doses (1.5-5 versus 36-100 megaunits) 
but fewer side effects (44,45,46).Treatment schedules should last 
at least 3 to 4 months in order to achieve a therapeutic 
response,but 6 months of continuous therapy are poorly tolerated; 
in this respect however conflicting reports have been published 
<47,48).Interferon can be administered once daily,three times 
weekly or on alternate days via the intramuscular or subcutaneous 
route.Although these aspects have not been compared in large 
patient series the results of various trials show that 
administration on alternate days or once daily does not produce 
substantially different results (49).Response to alpha-interferon 
usually occurred after 6-10 weeks of therapy and was often,but 
not always,accompanied by a two to three-fold increase in serum 
aminotransferase activity (18,50,51). 
Randomized controlled trials on alpha-interferon. 
The first randomized double-blind placebo-controlled trial with 
Table 2. Al{ila-interferon rank.mized oantrolled trials 
Author type dose treabnent cumulative patients seroconversion 
(reference) design MU schedule (estimated) (n) HBe(n) HBe(%) HBs(n) HBs(%) 
Schalm (52, 53) can ten 12->0.375 once daily, 14 10 2 20 0 0 
(i.m) 6 weeks 
albumin 10 4 40 0 0 
Anderson (54) lymphoblastoid 2.5->7.5 once daily, 238 14 2 14 0 0 
(i.m) (sqm) 4 weeks. 
no therapy 16 0 0 0 0 
Hoofnagle (55) recombinant 5 once daily or 560 16 3 19 0 0 
(alpha 2b) 10 every other 560 15 7 47 1 7 
(s.c) day,16 weeks. 31 10 32 1 3 
no therapy 14 2 14 0 0 
BarlJara (56) lymphoblastoid 5 sqm once daily, 28 748 30* 21 70 8 27 N 
(i.m) days, 3xweekly, 00 
20 weeks. 
no therapy 31 10 33 0 0 
rusheiko (57) recombinant 2.5 sqm 3xweekly, 306 
(alpha 2a) 5 sqm 3xweekly, 612 
(i.m) 10 sqm 3xweekly, 1224 
24 weeks. 14 1 7 0 0 
no therapy 5 0 0 0 0 
McDonald (58) recombinant 2.5 sqm 3xweekly, 306 9 1 11 1 11 
(alpha 2a) 5 sqm 3xweekly, 612 9 1 11 0 0 
(i.m) 10 sqm 3xweekly, 1224 14 4 29 1 7 
12-24 weeks. 
no therapy 9 0 0 0 0 
Lok (59) recombinant 2.5 sqm 3xweekly, 306 18 1 6 0 0 
(alpha 2a) 5 sqm 3xweekly, 612 18 4 22 0 0 
(i.m) 10 sqm 3xweekly, 1224 18 2 11 0 0 
12-24 weeks. 
no therapy 18 1 6 0 0 
Author type dose treabnent et.nnulative patients seroconversion 
(reference) design MU schedule (estimated) (n) HBe(n) HBe(%) HBs(n) HBs(%) 
Perez (60) recombinant 2.5 sqm 3xweekly, 306 6 4 67 0 0 
(alpha 2a) 5 sqm 3xweekly, 612 6 2 33 0 0 
(i.m) 10 sqm 3xweekly, 1124 6 0 0 0 0 
12-24 weeks. 
no therapy 6 1 17 0 0 
Iai (61) recombinant 10 sqm 3xweekly, 612 12 1 8 0 0 
(alpha 2a) 12 weeks. 
(i.m) vitamin B 12 1 8 0 0 
syrup. 
Alexander ( 62) lymphoblastoid 5-10 3xweekly, 1224 23 6 26 5 22 N 1.0 
(i.m) sqm 24 weeks. 
no therapy 23 0 0 0 0 
Carreno ( 63) recombinant 5.5 sqm once daily 710 10 2 20 0 0 
(alpha 2c) for 28 days, 
(i.m) twice a week, 
24 weeks. 
no therapy 10 0 0 0 0 
Pastore ( 64) can ten 0.07-0.1 once daily 308 14 8 57 0 0 
(i.m) pro kg. for 28 days, 
twice a week, 
2 months. 
no therapy 14 4 29 0 0 
* 5 patients withdrawn from the trial. 
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Cantell interferon was published in 1980 (52,53>.Although the 
numbers were small the results of this trial did not demonstrate 
a clinical relevance or a statistically beneficial effect of 
interferon treatment in chronic hepatitis B.As of the first 
quarter of 1989 11 other randomized controlled trials had been 
published (table 2) (54-64).From these trials several conclusions 
can be drawn:perhaps the most important concerns trial size:most 
are small,thereby increasing the risk of a type II error. 
Therapeutic response,as defined by a statistically significant 
increase in HBe-seroconversion,was achieved in a minority of the 
trials.The net increase in seroconversion rate achieved varies 
between 18 and 37 %.Seroconversion rates for the control groups 
vary from 0% to 33 %,clearly reflecting the patient populations 
selected to participate in the various trials.Spontaneous 
clearance of HBsAg occurs in about 1-3 % of the cases each 
year.Interferon therapy can,however,also produce complete 
'cure':HBsAg clearance occurs in 18% of patients (62,65). 
Meta-analysis of alpha-interferon therapy. 
A meta-analysis is the process of combining the results of 
several related studies.When adressing an important clinical 
question,such as the value of alpha-interferon therapy for 
chronic HBV infection,we normally combine pieces of knowledge 
coming from various sources.In a sense,a meta-analysis is nothing 
else than a rigorous,quantitative approach to this combination 
proces.In this chapter the use of meta-analysis is in the 
combination of small studies,with often conflicting results,so 
that more reliable conclusions can be obtained.The result of a 
meta-analysis is expressed as an odds ratio with its 95 % 
confidence interval.An odds ratio above 1 (and a confidence 
interval which excludes 1) suggests a positive treatment effect. 
Meta-analysis of the twelve published randomized controlled 
trials on alpha-interferon therapy is shown in table 3.For all 
individual studies,the odds ratio for HBeAg seroconversion with 
its 95 % confidence interval was calculated.Stratified exact 
analysis was carried out by the classic Mantel-Haenszel method. 
The overall odds ratio for HBeAg seroconversion is estimated to 
be 3.59 (95 % confidence interval:1.94 - 6.92) <p < 0.001) for 
alpha-interferon therapy.No heterogeneity between the studies was 
shown (p = 0.398).In figure 2 the individual contributions of 
the studies to the overall odds ratio are shown.Meta-analysis 
suggests that alpha-interferon is an effective drug for treatment 
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of chronic hepatitis B infection. 
Unfortunately the lack of adequate amounts of interferon for the 
open studies and the need for a further selection of patients for 
the small studies have led to the introduction of the concept of 
the 'responder' patient in literature.This is a patient who is 
considered highly likely to respond to interferon therapy on the 
basis of a number of interdependent biased characteristics 
related to the virus,the host and the interaction between the 
two (66).According to this hypothesis the ideal candidate should 
posses : 
A.Virus-related factors. 
l.Low levels of viral replication (low serum HBV-DNA). 
2.Recently acquired infection. 
B.Interaction between virus and host. 
l.Acute icteric hepatitis in the past. 
2.No HIV infection. 
3.No HDV infection. 
4.No immunodeficiency (e.g.agammaglobulinaemia,renal transplant 
recipients or the use of immunosuppressive drugs). 
C.Host-related factors. 
l.Caucasian,not infected at birth. 
2.Heterosexual. 
3.Female. 
4.Elevated serum transaminase activity. 
S.Liver histology:marked lobular and periportal activity. 
As discussed in chapter one,chronic hepatitis B infection can be 
divided into an early,an active and a late phase.In the early 
stage response to interferon therapy is unlikely to occur whereas 
in the active stage response usually takes place.A predictor 
accepted by most investigators is the initial level of viral 
replication:the best response is found for patients with low 
replication activity.This observation is compatible with the 
predictive value of the stage of the disease since high levels 
of viral replication characterize early disease and low levels 
active disease.Furthermore,high levels of viral replication are 
seen in immunodeficiency syndromes.Other factors said to be 
predictive,such as race,age at onset of the infection and sexual 
32 
Table 3. Alpha-interferon:meta-analysis of HBe-seroconversion in 
12 randomized controlled trials. 
Author Odds ratio 95% confidence Bar no. 
(reference) (HBe) interval for (figure 2) 
odds ratio 
Schalm (52,53) 0.39 0.03- 3.89 1 
Anderson (54) infinite 0.22-infinite 2 
Hoofnagle (55) 2.8 0.47-30.47 3 
Barbara (56) 4.76 1.47-16.76 4 
Dusheiko (57) infinite 0.01-infinite 5 
McDonald (58) infinite 0.33-infinite 6 
Lok (59) 2.51 0.29-120.72 7 
Perez (60) 2.42 0.20-137.65 8 
Lai (61) 1 0.01-85.55 9 
Alexander (62) infinite 1.35-infinite 10 
Carreno (63) infinite 0.19-infinite 11 
Pastore (64) 3.19 0. 55-21.66 12 
All studies 3.59 1.94- 6.92 13 
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fig 2.Therapeutic efficacy (HBe-seroconversion) for 12 
individual studies on alpha-interferon and estimated 
'overall'efficacy.Odds ratios are expressed as 95 % confidence 
limits.Numbers on x-axis: see table 3. 
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preference 1 are probably related to the above mentioned factors. 
Therefore one should interprete the data on predictive factors 
with extreme caution. 
Side effects. 
Antiviral therapy for chronic hepatit{s has advanced tremendously 
in the past ten years 1 with interferon rapidly becoming the 
cornerstone of treatment schedules.Therefore controlling the side 
effects of long-term interferon therapy has become important in 
view of patient compliance.Side effects are related to route of 
administration 1 treatment schedule and dosage.We will discuss the 
most frequently encountered side effects and possible solutions 
to these problems during alpha-interferon treatment. 
Injection technique. 
In our hospital the patients themselves inject interferon via 
the subcutaneous routerlike diabetics who administer their own 
insulin.Patients are provided with written instructions which 
describe how to prepare and administer an injection and how to 
cope with frequently encountered problems.To familiarize them 
with the use of sterile vials and syringes they receive a vial 
of sterile water to practise preparing a syringe for injection. 
The patient is instructed on an outpatient basis by a specially 
trained nurse.We advocate rotating the site of injection between 
the right and left upper leg and the abdomen;of special 
importance is the use of small needles to minimize tissue trauma. 
Disposable syringes without a dead space (Monoject 0.4 x 12 mm) 
are particularly suitable.Local irritation at the site of 
injection is often due to insufficient variation of the injection 
site.One patient developed a traumatic lesion of the lateral 
cutaneous nerve of the thigh 1 which resolved spontaneously within 
five months.Most minor problems can be solved by returning to the 
'interferon nurse' for instruction.In some cases we teach the 
partner to administer the interferon injection. 
Systemic side effects:the first week. 
During the first week of treatment most patients complain of an 
influenza-like syndrome with malaise 1 myalgia and high fever. 
Without treatment tachyphylaxis will develop in the first week 
and most symptoms will subside.First-week symptoms can be 
adequately suppressed by acetaminophen (500 mg six times daily) 
or indomethacin <Indocid Retard:75 mg twice daily).HLA-antigen 
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presentation,as reflected by serum beta-2 microglobulin levels, 
and depression of viral replication are not affected by either of 
these drugs (67).Acetaminophen and indomethacin can be 
discontinued after the first three days of interferon treatment; 
mild flu-like symptoms may persist. 
Systemic side effects:after the first week. 
During a course of 5 megaunits of alpha-interferon daily or 
thrice weekly systemic manifestations of the drug,such as 
fatigue,malaise,arthralgia,myalgia,anorexia,weight loss and hair 
loss,have been observed in up to 50 per cent of patients.Hair 
loss can persist for as long as two months after cessation of the 
drug.Leucocytopenia (granulocytopenia) is always observed;anaemia 
and thrombocytopenia occur in a minority of patients (59,68). 
Higher doses of alpha-interferon (36-100 MU/day) cause increased 
bone marrow toxicity.The antiviral action is not enhanced by 
elevating the dose in this dose range (44).Central nervous system 
side effects may occur,including an organic personality syndrome 
characterized by irritability and short temper and an organic 
affective syndrome marked by extreme emotional lability, 
depression and tearfulness.The organic nature of these changes is 
confirmed by electroencephalographic changes during interferon 
therapy,which remit after treatment is discontinued (69,70>.Loss 
of tendon reflexes,paraesthesia and peripheral sensory neuropathy 
have been observed,also when the EMG is normal.Liver functions 
(SGOT) can increase during interferon treatment without being 
indicative of imminent HBe-seroconversion (7l).In the animal 
model interferon depresses cytochrome p450 activity in liver 
tissue (72) .In man inhibition of antipyrine metabolism by 
exogenous interferon has been shown.Changes in the 
pharmacokinetics of drugs metabolized by cytochrome p450 can 
therefore be expected (73,74,75). 
Management of interferon-related side effects. 
Our patients used to give themselves the injection in the 
morning.It appears that such side effects as malaise and myalgia 
have decreased since our recommendation that the drug be 
injected in the evening.Most side effects reverse quickly on 
dose reduction or cessation of treatment.In case of clinically 
important side effects a 50 % dose reduction is prescribed.If 
side effects subside the dose is increased to 75 % of the 
original dose.In our experience with 75 patients treatment was 
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discontinued only once because of severe malaise.If adequate 
monitoring of therapy is provided alpha-interferon is a safe and 
well-tolerated drug. 
4.Conclusions. 
Single drug therapy with alpha-interferon is clearly a starting 
point for antiviral therapy for chronic hepatitis B.In contrast 
to other drugs alpha-interferon can promote HBsAg clearance. 
Clearly efficacy has to be increased either by selection of 
patients,on the basis of a model which describes the complex 
host-virus interaction more adequately,or by combination of 
alpha-interferon either with other immunomodulatory agents or 
with nucleoside analogues. 
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2.3 Adenine Arabinoside and Adenine Arabinoside Monophosphate. 
l.The agent. 
Adenine arabinoside is a purine analogue with potent antiviral 
activity.It inhibits the synthesis of HBV nucleic acid by acting 
as a faulty substrate,thus preventing DNA synthesis.It inhibits 
DNA-polymerase activity selectively,being more potent against 
viral than against mammalian cell polymerases.Due to the effect 
on host cell DNA synthesis and lymphocyte proliferation it is 
immunosuppressive (!).Because the solubility of the drug in water 
is very low,it must be administered by slow intravenous infusion 
in rather large volumes of fluid.The monophosphorylated analogue 
adenine arabinoside monophosphate (ARA-AMP) has a similar 
spectrum of antiviral activity but is at least a thousand-fold 
more soluble in water.ARA-AMP can be given as an intravenous 
bolus or an intramuscular injection.The more recent studies focus 
mainly on ARA-AMP. 
2.Mode of action. 
The clinical efficacy of ARA-A in systemic herpes infections has 
been proven.Before acyclovir became available ARA-A was the 
treatment of choice for systemic herpes infections and herpes 
simplex encephalitis (2,3).Antiviral activity against hepatitis 
DNA viruses has been shown in vitro and in vivo in woodchucks. 
Potent inhibition of endogenous and woodchuck DNA-polymerase 
activity by ARA-A triphosphate has also been demonstrated (4).In 
the woodchuck model,inhibition of viral replication by ARA-AMP 
was shown (5). 
3.Clinical trials. 
Results of open studies. 
The first use of ARA-A for treatment of chronic type B hepatitis 
was reported by Stanford University (6).Two patients with active 
viral replication (HBsAg,DNA-polymerase positive) received two 
courses of intravenous ARA-A in a dosage of 15 mg/kg/day for 9-14 
days.DNA-polymerase inhibition was approximately 50 % on day 3, 
75 % on day 7 and 90 % on day 14.When ARA-A was discontinued DNA-
polymerase activity returned to pre-treatment levels in one 
patient but remained negative in the other.This patient 
subsequently became HBsAg negative.Reviews of the use of ARA-A in 
open studies at Stanford have been presented by Scullard et 
al. (7,8,9).In the opinion of this group ARA-A is a more potent 
inhibitor of hepatitis B virus replication than human leucocyte 
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Table 1. Adenine arabinoside (ARA-A;ARA-AMP) ,raniamized controlled trials 
Author type dose treatment cumulative patients seroconversion 
(reference) design rrgjkgjday schedule (rrgjkg) (n) HBe(n) HBe(%) 
Bassendine (13) ARA-A 10 iv,10 days 100 7 3 42 
no therapy 6 0 0 
Hoofnagle (14) ARA-AMP 10 iv,5 days 165 10 4* 40 
ARA-AMP 5 im,23 days 
no therapy 10 2 20 
Yokosuka (15) ARA-A 10 iv,28 days 280 7 1 10 
iv,56 days 560 3 
no therapy 10 2 20 
Duzan (16) ARA-A 15 iv, 7 days 210 15 3 20 
7.5 iv,14 days 
placebo 15 1 7 
Weller (17) ARA-AMP 10 im,5 days 165 15 6 40 
5 im,23 days 
no therapy 14 0 0 
Perillo (18) ARA-AMP 10 im,s days 165 11 0 0 
5 im,23 days 
no therapy 11 1 9 
ARA-AMP 10 im,5 days 330 7 1 14 
5 im,23 days 
2 cycles 
no therapy 6 0 0 
Trepo (2o, 21) ARA-AMP 10 im,5 days 165 19 10++ 53 
5 im,23 days 
NaCl 0.9% im,28 days 18 5 28 
Garcia (22) ARA-AMP 5 im,28 days 420 24(<>) 2 9 
3 cycles 
Albumin sc,28 days 27 4 15 
3 cycles 
<> 2 patients lost to follow up. 
++ 2 patients reactivated; 42 patients entered the trial, reports on 37 patients. 
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interferon but permanent loss of hepatitis B virus replication is 
less likely with ARA-A than with interferon therapy. 
The1 first pilot studies of ARA-AMP were reported by Weller and 
Hoofnagle (lO,ll).ARA-AMP therapy resulted in a prompt decrease 
in HBV-DNA serum levels and DNA-polymerase activity when 
administered twice daily.Persistent response to therapy,however, 
was observed in only a minority of patients.The overall 
beneficial response to ARA-AMP therapy in seven uncontrolled 
studies is estimated at 11% (12). 
Randomized controlled trials. 
When randomized controlled trials were initiated ARA-A was 
already being used by several investigators to treat patients 
with chronic type B hepatitis.Although adenine arabinoside 
markedly reduced DNA-polymerase activity during treatment,in the 
majority of cases DNA-polymerase activity and other HBV markers 
returned to pre-treatment levels when ARA-A(MP) was 
discontinued.A matched controlled study showed an initial 40 % 
response rate (HBe-seroconversion) after a ten-day course of 
ARA-A (13).A summary of the main randomized placebo-controlled 
trials is given in table l.Hoofnagle initially found a beneficial 
effect of 4 weeks of ARA-AMP compared to no therapy.Extensive 
follow-up revealed reactivation in two patients who had 
initially responded.Ultimately,the authors could not demonstrate 
any benefit of 4 weeks of ARA-AMP therapy (14).Weller observed a 
beneficial response in 6!15 treated patients compared to none in 
14 untreated control patients.Interpretation of this trial is 
difficult because of concomitant viral infections.Two patients 
were infected with the Delta agent and one with the hepatitis A 
virus.Both viruses are known to interfere with hepatitis B 
replication and make interpretation of a therapeutic modality 
aimed at hepatitis B difficult (17).In France Trepo reported a 
25% increase in seroconversion rate after 28 days of ARA-AMP.A 
considerable number of patients dropped out of this study which 
makes interpretation hazardous (20,2l).Comparable results were 
reported by Ouzan who found that intravenous ARA-A led to a 13 % 
increase in seroconversion rate compared to controls (16).In 
these French studies patients who did not respond to therapy 
were given another course of ARA-A(MP) 6 months later.In both 
studies the net response rate increased after two courses to 
around 40 % compared to the initial control group.In a three-
part randomized trial Lok compared short (4-week) and long 
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Table 2. ARA-A/ARA-AMP:meta-analysis of HBe-seroconversion in 9 
randomized controlled trials. 
Author Odds Ratio 95% confidence Bar no. 
(reference) <HBe) interval odds (figure 1) 
ratio 
Bassendine (13) infinite 0.39-infinite 1 
Hoofnagle (14) 2.54 0.26-37.18 2 
Yokosuka (15) 0.46 0.10-10.51 3 
Ouzan (16) 3.36 0.23-196.60 4 
Weller (17) infinite 1. 38-infinite 5 
Perillo (18) 0.00 0:00-39.00 6 
infinite 0.02-infinite 7 
Trepo (20,21) 2.8 0.61-14.44 8 
Garcia (22) 0.53 0.04-4.13 9 
All studies 2.37 1.12-5.19 10 
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(initially 12,later 7-week) courses of ARA-AMP to interferon 
treatment.Sustained inhibition of viral replication was found for 
the patients receiving short courses of ARA-AMP or interferon but 
not in those on long courses of ARA-AMP.Side effects increased 
dramatically in the latter group (19). 
Meta-analysis of adenine arabinoside (ARA-A/ARA-AMP) therapy. 
Meta-analysis of the eight published randomized controlled 
trials on ARA-A(MP) therapy is shown in table 2.For all 
individual studies,the odds ratio for HBe-seroconversion was 
calculated with its 95 % confidence interval.Stratified exact 
analysis was performed by the classic Mantel-Haenszel method.The 
overall odds ratio for HBeAg seroconversion is estimated to be 
2.37 (95 % confidence interval 1.12 - 5.19) <p < 0.017) for ARA-A 
therapy. No heterogeneity between the studies was demonstrated (p 
= O.l).In figure 1 the relative contributions of the 8 trials to 
the overall odds ratio are shown.Meta-analysis suggests that 
ARA-A is an effective drug for the treatment of chronic hepatitis 
type B. 
Side effects. 
ARA-A and ARA-AMP have significant toxic side effects which are 
dose-related.In the case of long-term low-dose therapy,toxicity 
is related to the cumulative dose.The safe period of treatment 
probably does not exceed 4 weeks (23).Side effects can be grouped 
into three main categories:gastrointestinal,bone marrow and 
neurblogic.Prolonged or high-dose therapy causes anorexia,nausea 
and fatigue;vomiting and diarrhoea can also occur.Reversible bone 
marrow depression with leucopenia and thrombocytopenia has been 
reported.The most troublesome problem is the neuromuscular 
toxicity of ARA-A and ARA-AMP;at dosages in excess of 10 
mg/kg/day headaches,lethargy,stupor and tremors may develop. 
These symptoms can last several weeks and may be associated with 
EEG changes <24).A neuromuscular pain syndrome which affects 
mainly the nerves and the muscles of the back and lower 
extremities has been descibed (25,26).This syndrome,which can be 
severely disabling and may persist for months after therapy is 
discontinued,is probably due to axonal neuropathy.It has been 
suggested that patients with preexisting electromyographic (EMG) 
abnormalities are more likely to develop this syndrome (27,28). 
It rarely occurs when ARA-A is used to treat viral infections 
other than hepatitis.Toxicity is enhanced by the combination of 
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fig !.Therapeutic efficacy <HBe-seroconversion) in 8 individual 
studies on ARA-A(MP) and estimated 'overall' efficacy.Odds ratios 
are expressed as 95 % confidence limits.Numbers on x-axis:see 
table 2. 
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interferon and ARA-AMP (22). 
4.Conclusions. 
Adenine arabinoside and adenine arabinoside S'monophosphate are 
effective in inhibiting hepatitis B virus replication.Meta-
analysis of randomized controlled trials shows enhancement of 
HBe-seroconversion rates compared to untreated control patients. 
Neurotoxicity is a major problem which can be managed partly by 
pre-treatment EMG monitoring.Since drug toxicity is a dose-
related problem,limitation of the cumulative dose and avoidance 
of high peak plasma concentrations can partly prevent ARA-A 
toxicity.A relatively safe therapeutic regimen consists of a 4-
week course followed by a six-month rest period before the course 
is repeated.The study by Lok suggests that if ARA-AMP is used for 
a period of more than 4 weeks,its immunosuppressive properties 
become more dominant in relation to its antiviral 
properties.This may result in a lower therapeutic response.In 
the event of treatment failure after one course of ARA-A,the 
patient can be treated again with the same agent (16,19,20).A 
substantial number of these patients will respond to this second 
course of therapy.In some studies a first course of ARA-A(MP) did 
not induce seroconversion of DNA-polymerase or HBeAg although 
post-treatment levels of viral replication were substantially 
lower in treated patients compared to untreated controls. 
Insufficient activity of the drug in patients with high levels of 
viral replication could possibly explain the favourable response 
to a second treatment course. 
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2.4 Corticosteroid withdrawal. 
The observation that discontinuation of corticosteroid therapy in 
patients with chronic hepatitis type B often results in remission 
of the disease has led to the hypothesis that abrupt withdrawal 
of treatment causes an immune rebound effect followed by 
clearance of the virus,the mechanism being enhanced hepatocyte 
expression of viral antigens during steroid therapy (l).After 
steroid withdrawal immunocompetence is restored and parenchymal 
cells which express target viral antigens are destroyed (2).In 
uncontrolled pilot studies this hypothesis was further explored: 
20 patients followed a tapered dose schedule consisting of 60,30, 
10 and 5 mg prednisone per day,each dose for 2 weeks and a total 
of 10 weeks of treatment.Ten of 20 treated patients became HBe-
negative.In addition there was a significant drop in HBsAg titre 
and transaminase activity in the prednisone-treated group.However 
5!20 patients had a period of hepatic decompensation (4 with 
ascites-two of whom also had encephalopathy-,one haemorrhage 
from oesophageal varices with encephalopathy).Hepatic 
decompensation was closely related to the presence of chronic 
active hepatitis with cirrhosis (3).In a study of 12 patients 
discontinuation of immunosuppressive therapy was associated with 
a bout of hepatitis four weeks after withdrawal.Interestingly the 
flare of hepatitis only occurred in HBeAg-positive patients.HBeAg 
was eliminated in 8/12 patients.However one patient died of liver 
failure and 2 patients experienced a deterioration of the liver 
disease (increasing bilirubin,ascites) (4).The steroid withdrawal 
hypothesis was further investigated in a double-blind randomized 
placebo-controlled study (5).Fifteen patients without a history 
of decompensated liver disease participated in this study. 
Histologically all had chronic persistent or mild to moderate 
chronic active hepatitis.Ten patients received prednisolone (60 
mg/day) for two weeks,followed by 30 mg/day for another two weeks 
with sudden withdrawal.No significant effects on viral 
replication were observed during prednisolone therapy. 
Aminotransferase activity decreased significantly during 
treatment but exhibited a severe rebound to above-initial levels 
after termination of the drug.Follow-up at one year showed no 
improvement in biochemical or serological features of the 
disease.Follow-up liver biopsies revealed deterioration in 4/7 
treated patients vs 0!5 untreated control patients.In conclusion 
this treatment has no beneficial effect and may in fact be 
harmful. 
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2.5 Acyclovir. 
l.The agent. 
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Acyclovir or 9-(2-hydroxyethoxymethyllguanine is a non-cyclic 
guanosine analogue that specifically inhibits viral DNA synthesis 
but barely interferes with host cell DNA synthesis.A systematic 
programme which was initiated at Burroughs Wellcome to prepare 
synthetic nucleoside analogues with a non-cyclic side chain led 
to the discovery of acyclovir in 1974 (1,2).Acyclovir can be 
administered via the topical,oral and intravenous routes.In the 
case of oral administration absorption of acyclovir is slow and 
incomplete,with a bioavailability of 15 to 30%.Steady state 
levels of about 2.5 uM are achieved with 200 mg acyclovir every 4 
hours (3).Five mg acyclovir/kg body weight given intravenously 
yielded peak levels of about 35 uM;peak serum concentrations 
increased to 90 uM after 15 mg/kg body weight.Renal excretion is 
by filtration and active secretion (4). 
Descyclovir (6-deoxyacyclovir) is an oral pro-drug of acyclovir 
without antiviral activity.Descyclovir,which is almost totally 
absorbed from the gastrointestinal tract,is converted by xanthine 
oxidase to acyclovir and by aldehyde oxidase to the inactive 
metabolites 8-hydroxy-6-deoxyacyclovir and 8-hydroxy-acyclovir. 
Since the human liver contains low levels of aldehyde oxidase, 
conversion of 6-deoxyacyclovir to acyclovir is the principal 
metabolic pathway in man.Peak plasma levels of acyclovir after 
250 mg descyclovir orally every six hours are around 40 uM (5,6). 
2.Mode of action. 
The acyclic structure of acyclovir explains its effect as a 
terminator of DNA synthesis because it lacks the 3'hydroxyl group 
essential for DNA elongation.For acyclovir to act as an 
inhibitor of viral DNA synthesis,it must be phosphorylated to 
the monophosphate by a viral thymidine kinase.The selective 
antiviral effect of acyclovir on viral DNA-polymerase is due to 
its preferential phosphorylation by cells expressing a viral 
thymidine kinase (?).Acyclovir enters the infected cell by 
passive diffusion;after monophosphorylation redistribution to 
the blood is hampered because the monophosphate derivative does 
not easily cross the cell membrane.Acyclovir binds 200-fold 
better to and is phosphorylated 3.106 times more easily by the 
viral than the cellular thymidine kinases (8,9l.The acyclovir 
monophosphate is further metabolized to the triphosphate by 
cellular enzymes (10). 
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Acyclovir triphosphate inhibits all human herpes viral DNA 
polymerases in vitro <11,12,13).Viral thymidine kinase is not 
encoded by the human cytomegalovirus,which is relatively 
insensitive to acyclovir <14,15).Still some inhibitory effects of 
acyclovir on cytomegalovirus have been shown in vitro (16, 
17).Like cytomegalovirus the human hepatitis B virus does not 
encode for a thymidine kinase in the infected cell although there 
is evidence for protein kinase activity associated with the 
complete virion (18).Some authors have suggested that in certain 
settings cellular enzymes may be able to phosphorylate acyclovir 
sufficiently to allow its activation in the absence of a virus-
specified thymidine kinase (19,20).In vitro acyclovir 
triphosphate inhibits human hepatitis B virus and a closely 
related virus in woodchucks (2l).In chronically infected Peking 
ducks acyclovir inhibits DNA-poiymerase activity as long as the 
drug is administered (22). 
3.Clinical trials. 
Open studies of intravenous acyclovir. 
In a dose-response study six patients were treated with acyclovir 
(5-15 mg/kg every 8 hours) given as an intravenous bolus or one-
hour intravenous infusion for up to seven days.Two patients 
receiving 10 and 15 mg acyclovir/kg showed 50 % inhibition of 
DNA-polymerase activity.The mean plasma acyclovir concentrations 
were 5.0 and 13.2 uM,respectively;the latter was associated with 
a more marked effect,suggesting a dose-response relation (23). 
Three patients received doses that increased from 15 mg/kg/day 
to 45 mg/kg/day for 1-2 weeks.Inhibition of DNA-polymerase 
activity was 60 - 80 % during all courses;in fact,DNA-polymerase 
activity could not be detected for four months in one patient.A 
dose-response relationship in the dose range 15 to 45 mg/kg/day 
was less evident in these three patients <24).Trepo treated 10 
patients with acyclovir (45 mg/kg/day administered via a 
continuous infusion) for 21 days and found a transient drop in 
DNA-polymerase activity in 9 patients.In two patients a trend 
towards a prolonged 50 % reduction in DNA-polymerase activity 
was observed after therapy.Both patients had low pre-treatment 
DNA polymerase activity.In a follow-up study six patients with 
low grade virus replication (HBV-DNA positive,low DNA-polymerase 
activity) were evaluated.DNA-polymerase activity decreased 
during therapy and exhibited a further reduction over the next 
two months.However in five patients DNA-polymerase activity 
57 
reactivated in the course of the extended follow-up (25,26). 
Open studies of oral acyclovir and descyclovir. 
Oral acyclovir was ineffective in depressing DNA-polymerase 
activity (26,27).Four patients received 250 mg descyclovir orally 
every 6 hours for 10 days.No depression of DNA-polymerase 
activity during therapy was noted in three patients.In one 
patient HBe-seroconversion was observed,but retrospectively this 
patient had unstable disease at the start of the study (28). 
Randomized controlled trials with acyclovir and descyclovir. 
Two small randomized controlled studies on the effect of 
intravenous acyclovir in chronic type B hepatitis have been 
performed (29,30,3l).Results and treatment schedules are 
summarized in table 1. 
Continuous infusion of acyclovir (45 mg/kg/day) resulted in a 
mean decrease in DNA-polymerase activity and serum HBV-DNA of 12 
and 35 per cent,respectively,after 28 days.Therapy was associated 
with seroconversion of HBe in 33% of patients (5/15),HBV-DNA in 
16% (2/12) and DNA-polymerase in 33% (5/15).Seroconversion rates 
for controls were 13% (2/15),7% (1/13) and 0% (0/11), 
respectively;these differences did not reach statistical 
significance (30). 
In a study by Guarescio the effect of a continuous or 
intermittent infusion (three times daily) of 45 mg/kg/day for 28 
days was compared to that of no therapy.No effect on viral 
replication was found after the continuous infusion but there 
was a 20 % inhibition of DNA-polymerase activity after the 
intermittent infusions of 45 mg/kg/day acyclovir,although the 
difference was not statistically significant.Compared to 
untreated control patients no apparent beneficial effect on 
HBe-seroconversion was observed (31). 
Meta-analysis of acyclovir therapy. 
Meta-analysis of the two randomized controlled trials on the use 
of acyclovir in chronic hepatitis type B is shown in table 2.For 
the individual studies,the odds ratio for HBeAg seroconversion 
was calculated with its 95 % confidence interval.Stratified exact 
analysis was done by the classic Mantel-Haenszel method.Overall 
odds ratio with regard to HBe-seroconversion is estimated to be 
1.38 (95% confidence interval:0.32- 6.46) <p = 0.43) for 
acyclovir therapy.In figure 1 the contributions of the two 
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Table 1. Acyclovir, ran:kmized cxxrt::rolled trials. 
Author dose treatment 
(reference) ngjkgjday schedule 
Alexander (30) 45 
Guarescio (31) 45 
continuous, 
infusion 
no therapy 
continuous 
or 8-hour 
infusion 
placebo 
days cumulative patients seroconversion 
(n) (ngjkg) (n) HBe(n) HBe(%) 
28 1260 15 5 33 
15 2 13 
28 1260 11 2 18 
9 3 33 
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Table 2. Acyclovir:meta-analysis of HBe-seroconversion in 2 
randomized controlled trials. 
Author Odds Ratio 95% confidence Bar no. 
(reference) (HBe) interval for (figure 1) 
odds ratio 
Alexander (30) 3.12 0.40-39.97 1 
Guarescio (31) 0.46 0.03-5.39 2 
All Studies 1.38 0.32-6.46 3 
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fig !.Therapeutic efficacy (HBe-seroconversion) determined in 2 
individual studies on acyclovir and estimated 'overall' efficacy. 
Odds ratios are expressed as 95 % confidence limits.Numbers on 
x-axis:see table 2. 
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studies to the overall odds ratio are shown.Although there are 
only two studies meta-analysis does not suggest beneficial 
effects of single drug therapy with acyclovir. 
Side effects. 
Acyclovir is a relatively non-toxic drug compared to,for 
instance,adenine arabinoside.Local irritation and phlebitis at 
the site of infusion have occurred after high dose intravenous 
administration and were probably due to the high pH of the 
acyclovir solutions (32,33).The major adverse effect of acyclovir 
involves renal function.Reversible elevation of serum creatinine 
has been found,especially when doses exceeding 5 mg/kg are given 
intravenously every 8 hours.Dehydration,pre-existing renal 
insufficiency and high dose bolus infusions can enhance the risk 
of crystallization of acyclovir in renal tubules or collecting 
ducts,causing a reversible crystalline nephropathy (1,34,35). 
Case reports suggest a relation between the use of acyclovir and 
central nervous system toxicity,including delirium,tremors, coma 
and abnormal electroencephalograms as well as acute psychiatric 
disturbances.Slight increases in aminotransferase levels, 
nausea,abdominal discomfort,diarrhoea,dry skin,rashes and 
decreased haematological indices during high-dose intravenous 
acyclovir treatment have been reported (36,37,38,39). 
4.Conclusions. 
Acyclovir triphosphate inhibits woodchuck and human hepatitis B 
virus DNA-polymerase activity in vitro.In vivo inhibition by 
acyclovir has been shown for Peking duck and human hepatitis B 
virus DNA-polymerase activity.In contrast to the herpes viruses 
the hepatitis B virus does not encode for a specific thymidine 
kinase.Therefore acyclovir is phosphorylated by cellular kinases 
to active acyclovir triphosphate.Because of this lack of 
specificity the drug is only moderately effective at relatively 
high doses;one small study indicated that intermittent infusions 
are preferable to continuous infusions,suggesting that peak serum 
levels are more important than steady state serum levels <32).No 
apparent long-term effect on HBe-seroconversion has been shown in 
randomized controlled studies.The drug is non-toxic if adequate 
precautions against renal toxicity are taken.Single drug therapy 
with acyclovir or descyclovir does not seem to be justifiable 
for chronic type B hepatitis. 
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2.6 Conclusions. 
Single drug therapy with alpha-interferon is clearly a starting 
point for antiviral therapy for chronic hepatitis B.In contrast 
to other drugs alpha-interferon can promote HBsAg clearance. 
Efficacy has to be increased either by selection of patients,on 
the basis of a model which describes the complex host-virus 
interaction more adequately,or by combining alpha-interferon 
with either other immunomodulatory agents or nucleoside 
analogues.Of the available nucleoside analogues acyclovir and 
adenine arabinoside are effective in inhibiting hepatitis B virus 
replication,but the use of ARA-A is limited because of severe 
neurotoxicity.Acyclovir is non-toxic if adequate precautions 
against renal toxicity are taken.Our studies concentrated on the 
combination of alpha-lymphoblastoid interferon and acyclovir. 
Chapter 3. 
Antiviral effect of acyclovir <oral and intravenous> and 
descyclovir in chronic hepatitis B. 

Chapter 3. 
Introduction. 
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Single drug treatment with alpha-interferon,adenine arabinoside 
or its monophosphate derivative has resulted in predictable but 
often only partial suppression of HBV-associated DNA-polymerase 
in patients with chronic hepatitis B and active virus replication 
(1).The virustatic agent acyclovir was also found to inhibit 
HBV-DNA-polymerase activity (2,3).In view of the fact that 
acyclovir is relatively non-toxic and allegedly does not 
interfere with the immune system as well as the availability of 
an oral prodrug that is easily absorbed,we investigated the 
effect of this drug more fully in patients with chronic HBe-
positive hepatitis. 
Methods. 
Patients with chronic hepatitis B and stable HBeAg and DNA-
polymerase serum levels for at least six months participated in 
the study.Patients who had undergone a liver biopsy prior to 
entry exhibited HBcAg in the nuclei of the hepatocytes.Six 
patients,including one individual with chronic renal failure on 
dialysis,received acyclovir orally in a dose of 800 mg four 
times daily for four weeks (study I).Intravenous acyclovir (15 
mg/kg body weight in a 1-hour infusion of 0.5 1 of fluid,twice 
daily) was administered to 11 patients for a period of 4 weeks 
(study II).Twelve patients were selected to participate in study 
III:six patients received deoxy-acyclovir orally in a dose of 
250,375 or 500 mg 3 times daily for two weeks.In each case the 
three treatment periods were separated by a two-week wash-out 
period.Six control patients received no treatment;they were 
followed simultaneously. 
In all studies blood samples were taken twice weekly for 
monitoring of virus replication (DNA-polymerase activity,HBeAg) 
,AST and serum creatinine levels.DNA-polymerase activity in serum 
was measured by standard methods and expressed as the P/N ratio 
(cpm patient sample/cpm normal control sample) (4).HBsAg and 
HBeAg were determined by radioimmunoassay (Abbott,Ill,USA).HBeAg 
was assessed in a dilution of serum that was constant for each 
patient;this dilution was chosen such that pre-treatment sera had 
a P/N ratio of 10 +/- 2.A PIN ratio below 2.1,in undiluted serum, 
was considered a negative result.For studies I and II,data 
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Table 1.Features of patients prior to acyclovir and descyclovir 
treatment. 
Sex,male 
Homosexual 
Duration of HBsAg (yr) * 
HBsAg titre no-3>+ 
HBeAg (P/N ratio)+ 
DNA-p (P/N ratio)+ 
HBcAg in nuclei (%)* 
Bilirubin ()J.IUOl/l)* 
(normal < 17) 
AST (IU/l)* 
(normal < 30) 
Cirrhosis 
nt not tested 
* mean 
+ geometric mean 
ACV(oral) 
(n=6) 
6 
4 
5 
5.7 
7.2 
4.9 
20 
9 
58 
2 
ACV(iv) 
(n=ll) 
10 
4 
3.3 
2.2 
8.5 
25.1 
39 
18 
119 
1 
DCV(oral) 
(n=6) 
6 
4 
2.7 
nt 
8.3 
14.7 
24 
12 
63 
2 
Control 
(n=6) 
4 
1 
3.0 
nt 
6.7 
6.7 
20 
11 
40 
1 
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before,during and after treatment were analysed by the Wilcoxon 
matched pairs test.For study III the difference between the 
first and last days of treatment was calculated for the three 
dose groups and compared to the difference found for the control 
patients followed in the same period by means of the Wilcoxon/ 
Mann-Whitney rank-sum test.Differences between the first and 
last days of treatment within the groups were analysed by a 
Wilcoxon matched pairs test.Before analysis the DNA-polymerase 
ratios underwent log transformation. 
Results. 
Features of patients at entry into the study are summarized in 
table l.No major differences were observed between the groups, 
although the level of virus replication and the activity of the 
liver disease tended to be higher in patients receiving 
intravenous acyclovir. 
Oral acyclovir did not influence levels of viral replication. 
Intravenous acyclovir had an inhibitory effect on serum DNA-
polymerase activity during the first three weeks of treatment 
(p < 0.05) but this effect was not sustained during the fourth 
treatment week and disappeared after treatment was discontinued. 
No effect on serum HBeAg was observed.The effects of oral and 
intravenous acyclovir on HBeAg and DNA-polymerase activity are 
shown in figure 1. 
Figure 2 shows the effects of 250, 375 and 500 mg of descyclo-
vir,administered 3 times daily for two weeks,on markers of viral 
replication in individual patients.Therapy was associated with 
3%,19% and 9% inhibition of HBeAg in the 250,375 and 500 mg 
groups,respectively.In untreated controls HBeAg increased 
approximately 10 %. DNA-polymerase inhibition was 7%, 32% and 
20%,respectively in the treatment groups compared to an increase 
ranging between 5 and 55 % in the control group.These differences 
did not reach statistical significance.No significant effects on 
either DNA-polymerase activity or HBe-seroconversion were shown. 
Tolerance for oral acyclovir and descyclovir was good.The main 
complication of intravenous therapy was thrombophlebitis.No 
patients were withdrawn from the study because of suspected side 
effects. 
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ucyclolllr 2x15 mg/kg 111 
15 
WEEKS 
ocydo11lr 2x15 mg/kg iv 
D<:ydo11ir llxaoo mg 
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fig l.Inhibitory effect of oral acyclovir (800 mg four times 
paily> and intravenous acyclovir (15 mg/kg twice daily> on DNA-
polymerase activity <left panel> and HBeAg (right panel).Data are 
expressed as GMT +/- SEM. 
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fig 2.Inhibitory effect of oral descyclovir (250 mg, 375 mg or 
500 mg three times daily) on DNA-polymerase activity (left 
panel) and HBeAg (right panel) in individual treated patients 
compared to untreated control patients. 
72 
Discussion. 
Oral acyclovir is ineffective in chronic hepatitis B,probably 
because of inadequate serum levels as a result of poor absorption 
of the drug.In pharmacokinetic studies of patients without liver 
disease serum levels of about 100 umol were found after an 
intravenous infusion of 15 mg/kg body weight in one hour,whereas 
serum levels after oral administration were usually below 20 
umol (S).In our study four weeks of intravenous acyclovir had a 
transient inhibitory effect on serum DNA-polymerase activity and 
no effect on serum HBeAg.Serum levels of acyclovir after 
descyclovir were higher than those after oral acyclovir but 
approximately four times lower than those after high-dose 
intravenous acyclovir (6).Descyclovir has only a modest effect 
on hepatitis B virus replication and no effect on seroconversion. 
In conclusion single drug treatment with oral acyclovir or 
descyclovir is not a valid option for patients with chronic 
hepatitis type B. 
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Acyclovir enhances the antiviral effect of interferon in chronic 
hepatitis B. 
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Antiviral agents may become the treatment of choice for chronic 
hepatitis B with active virus replication,since induction of 
virus latency - characterised by the disappearance of hepatitis-
B e antigen (HBeAg)- is associated with virtual disappearance of 
symptoms and infectivity as well as inactivation of the liver 
disease (1,2). 
Single-drug treatment with interferon,adenine arabinoside (ARA-
A),or ARA-A monophosphate has resulted in predictable,but often 
only partial,suppression of hepatitis-B-virus (HBV) associated 
DNA-polymerase;after treatment a state of virus latency occurs 
only occasionally.Severe side-effects appear to prohibit the use 
of large doses or combinations of drugs (3). 
The observation that the relatively non-toxic virustatic agent, 
acyclovir,inhibited REV-DNA-polymerase prompted us to compare 
acyclovir with interferon and subsequently to evaluate combined 
treatment with acyclovir and interferon (4). 
Our preliminary results suggest that combined treatment strongly 
suppresses not only DNA-polymerase but also HBeAg;such therapy 
appears promising for induction of a state of virus latency. 
Patients and methods. 
Twelve patients with chronic hepatitis B and active virus 
replication participated in the study.All had HBeAg and DNA-
polymerase in their serum for at least 6 months,and the 11 who 
had had liver biopsies before the study had HBcAg in the nuclei 
of hepatocytes. 
Six patients were given a 4-week course of intramuscular alpha-
interferon and,after a month without treatment,a 4-week course 
of intravenous acyclovir.The remaining 6 patients initially 
received acyclovir and then interferon.The dose of acyclovir 
administered was 15 mg/kg in 0.5 litres of fluid twice daily. 
Interferon was given intramuscularly in a dose of 2.5 MU/m2 once 
daily;the dose was adjusted downwards according to tolerance. 
Fluid intake during acyclovir treatment was kept above 
3 litres/24 h to prevent renal toxicity.Paracetamol 500-1000 mg 
was given 1 h before interferon to minimise its side-effects. 
Blood was taken twice a week for monitoring virus replication 
(DNA-p, HBeAg), renal function (creatinine), leucocyte and 
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Table l.Features of patients before specific therapy. 
Acyclovir Interferon 
<n=ll)* <n=l0)* 
Male,sex 10 9 
Homosexual 4 4 
Duration of HBsAg (yr)+ 3.3 4 
HBsAg <titre.lo-3 >++ 2.2 2.3 
HBeAg (P/N)++ 8.5 8.8 
DNA-polymerase (P/N)++ 25.1 34 
HBcAg in nuclei (%)+ 39 44 
Bilirubin (llffiOl/1)+ 18 9 
Aspartate aminotransferase ( IU/1 )+ 119 71 
Cirrhosis 1 1 
Interferon 
+acyclovir 
(n=5) 
5 
1 
3.2 
5.2 
9.2 
28.7 
55 
17 
117 
1 
* 3 Patients received only one treatment course because they 
became DNA-polymerase negative after the first treatment. 
+ Mean. 
++ Geometric mean 
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granulocyte counts.DNA-polymerase was measured in serum with a 
standard method and expressed as PIN ratio (cpm patient sample 
lcpm normal control serum).HBeAg was measured with radio-
immunoassay (Abbott) in a serum dilution constant for each 
patient;this serum dilution (5, 25, 125, or 625) was chosen so 
that pretreatment sera had a PIN ratio of 10±2.A PIN ratio of 
less than 2.1 was considered a negative result. 
Five patients with persisting active viral replication after two 
treatment courses received the combined treatment of interferon 
and acyclovir.Interferon was given for at least 8 weeks at the 
maximum tolerable dose used in the first study.Acyclovir was 
started 2 days after interferon,when fever and malaise had 
subsided;the dose was also the same as that given in the first 
course (15 mglkg twice daily). 
For analysis,all P/N ratios were log-transformed.Means were 
taken of two consecutive values before treatment <x1>,for the 
1st and 2nd weeks of treatment <x2>,and 3rd and 4th weeks of 
treatment <x3),and for the 2nd and 3rd weeks after treatment 
<x4).For each patient,differences between x1 and x2,x1 and x3 
and x1 and x4 were calculated.For comparison within the group, 
Student's t-test was used to test the significance of these 
differences.Comparison of the combination treatment with 
acyclovir alone or interferon alone was done for the 5 patients 
who received all three treatments. 
Results. 
Features of the patients at entry into the study are summarised 
in table l.No major differences in virus markers were observed 
between the groups . The activity of the liver disease tended to 
be lower in patients assigned to interferon,but the difference 
was not significant. 
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fig l.Effects of interferon (i----1) and acyclovir (0----0) on 
serum HBV-DNA-polymerase and HBeAg.Both drugs induce a 
significant depression in DNA polymerase; the effect on HBeAg is 
significant only for acyclovir. 
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Figure 1 summarises the effects of single-drug treatment on 
hepatitis-B virus markers.Both interferon and acyclovir 
significantly depressed DNA-polymerase;this effect was achieved 
in the first 2 weeks of treatment.DNA-polymerase levels tended to 
rise after discontinuation of treatment.In 6 patients (4 with 
initial acyclovir,and 2 who started with interferon),however, 
DNA-polymerase remained negative 6 months after initial therapy. 
In addition,acyclovir treatment was associated with a significant 
fall in HBeAg (apparent in the 3rd and 4th weeks),which persisted 
in the month following treatment.Six months after treatment 5 
patients (3 acyclovir,2 interferon) had become HBeAg negative. 
Side-effects necessitated lowering the dose below 80% of the 
original dose in 3 instances of each therapy.For interferon, 
malaise and fatigue were the reasons for dose adjustment; 
difficulties with the intravenous administration of acyclovir 
caused suboptimum dosage in outpatients.Treatment had to be 
discontinued prematurely once with interferon (extreme fatigue) 
and once with acyclovir (severe thrombophlebitis).Apart from 
leucopenia,no major abnormalities in laboratory-test results 
were observed during antiviral therapy. 
The effects of combination treatment with interferon and 
acyclovir are shown in figure 2.In addition to a rapid fall in 
DNA-polymerase,a significant depression in HBeAg levels was 
apparent in the first 2 weeks of treatment,with a further fall 
thereafter under continued interferon treatment.In patients who 
received all three treatments,the combination therapy was 
significantly more effective in depressing DNA-polymerase and 
HBeAg in the 3rd and 4th weeks of treatment than either 
interferon or acyclovir alone.Four patients became DNA-polymerase 
negative,and subsequently 3 of them became HBeAg negative.The 
absence of these markers of active viral replication have 
persisted for a mean period of follow-up of 6 months (range 1-12 
months). 
Tolerance of the combination therapy when administered as 
described above was similar to that seen with single-drug 
therapy,with fatigue and thrombophlebitis as major complications. 
No patient,however,failed to complete the full combination 
treatment because of side-effects. 
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fig 2.Effects of the combination interferon/acyclovir on DNA-
polymerase (upper panel) and HBeAg (lower panel).Note the more 
profound and persistent effect of combination therapy,compared 
to single-drug treatment,in 5 patients receiving all three 
treatments. 
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Discussion. 
These findings confirm the reported antiviral effect of acyclovir 
on hepatitis B virus replication in a larger group of patients 
and suggest that acyclovir also depresses HBeAg synthesis (4). 
Moreover,a combination of acyclovir and interferon was 
significantly more effective in depressing HBV-DNA-polymerase 
and HBeAg. 
Induction of long-term negativity of DNA-polymerase and HBeAg may 
be a prerequisite for an antiviral regimen that converts a state 
of active viral replication into virus latency in a high 
proportion of patients.Single-drug therapy with interferon,ARA-
A,or acyclovir usually results in only partial depression of 
DNA-polymerase and HBeAg.The results of this study suggest that 
combination therapy is more effective in suppressing viral 
replication;this may well improve the chance that transition of 
active viral replication to virus latency will follow. 
Tolerance to the combination treatment was remarkably good, 
provided that acyclovir was started after the initial side-
effects of interferon therapy had worn off.The excellent 
tolerance of the combination of acyclovir and interferon is in 
striking contrast to that reported of the combination of 
interferon and ARA-A;clinical investigation of the latter 
regimen was stopped because of unacceptable toxicity (3). 
Our encouraging results still require confirmation in a larger, 
controlled trial.The need to give acyclovir intravenously twice 
daily for at least 2 weeks makes such a study difficult.However, 
the recent development of an oral prodrug of acyclovir (5),which 
is well absorbed and gives rises to acyclovir blood levels in the 
range of intravenous acyclovir,will probably overcome this 
difficulty. 
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Introduction. 
The prognosis of a patient with chronic hepatitis type B is 
mainly determined by the long-term complications of the 
infection: the development of liver cirrhosis and hepatocellular 
carcinoma.Therapeutic intervention can be indicated not only to 
improve long term prognosis but also to treat clinically 
important complaints such as fatigue and blood contagiousness. 
Theoretically therapy aimed at eradication of the virus came 
available by the discovery of interferon by Isaacs and Lindeman 
in 1957 (!).Approximately fifteen years later, sufficient 
quantities of the drug are now available for clinical evaluation. 
In practice,treatment with interferon alone appears effective in 
only a minority of patients with chronic hepatitis B (2). 
However combination therapy of interferon with another antiviral 
agent may lead to synergistic effects compared to either drug 
alone as has been shown for several viral infections in vitro 
(3,4).Inhibition of hepatitis B replication was shown for 
interferon and acyclovir respectively in earlier studies;however 
markers of viral replication often relapsed to their initial 
levels after therapy C5-9).In a pilot study we found that the 
combination of interferon and acyclovir could induce a state of 
virus latency (HBe-seroconversion) in 80 % of treated patients 
(lO).HBe-seroconversion was accompanied by an improvement in 
clinical, biochemical and histological manifestations of the 
disease.The prognosis of these patients probably can become 
excellent if cirrhosis has not developed and no HBV-DNA can be 
detected in serum and no free or integrated HBV-DNA can be 
detected in the liver. 
To document the validity of these encouraging therapeutic 
results we have performed a randomised controlled study using the 
combination of alpha-lymfoblastoid interferon (Wellferon) and 
descyclovir (BW 515), an oral prodrug of acyclovir (11). 
Descyclovir does not have any intrinsic antiviral activity of its 
own but is converted by hepatic xanthine oxidase to acyclovir. 
This paper reports on virus elimination and reactivation till 32 
weeks of observation. 
Methods. 
Patients. 
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Patients who participated in this study all had chronic HBsAg 
positive liver disease and showed active viral replication as 
shown by the presence of HBsAg and HBeAg and/or the presence of 
DNA-polymerase activity in serum. 
The main exclusion criteria for participation in the trial were: 
age under 18 years or above 65 years,recent alcohol or drug 
addiction,decompensated liver disease (ascites,encephalopathy, 
variceal bleeding),serious other diseases,recent antiviral or 
immunosuppressive therapy.Patients who were positive for HIV 
antibodies were accepted if they belonged to class I or II of the 
Walter Reed c1assification,which implies normal immune reactivity 
(12).All patients signed an i~formed consent form after which 
they were randomised in blocks of six to either treatment or 
control.Follow-up during therapy was weekly;after therapy had 
stoppped and in untreated control patients,monthly monitoring was 
done till one year after entry to the study. 
The study was appproved by the Medical Ethics Committee of the 
participating hospitals. 
Therapy. 
Treated patients received alpha-lymphoblastoid interferon 
(Wellferon> 5 MU once daily subcutaneously for sixteen weeks in 
combination with descyclovir <BW515) twice daily 1 gram orally 
for 8-16 weeks;during the first three days of therapy all treated 
patients received indomethacine (Indocid RetardR) 75 mg twice 
daily orally.Patients administered themselves interferon like 
diabetics insulin.Treatment was stopped if the HBeAg test was 
repeatedly negative (HBe-seroconversion) or if side effects were 
not tolerated.Control patients received no treatment. 
During therapy patients were tested weekly for HBeAg,SGOT, 
kreatinin,leucocytes and granulocytes.After therapy and in 
control patients,blood testing was done four-weekly.At each visit 
serum was prepared and stored at -20oC for HBV-DNA analysis. 
Laboratory methods. 
HBsAg and HBeAg were measured with a standard radioimmunoassay 
(Abbott,Ill.).For quantification,HBeAg was measured in a constant 
serum dilution for each patient.This dilution was chosen so that 
pre-treatment sera showed a P/N ratio (cpm patient sample/cpm 
negative control sample) of approximately 12.A P/N ratio below 
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2,1 in undiluted serum was considered a negative test.DNA-
polymerase activity was measured by the method of Howard as 
modified by Fang (13),and also expressed as P/N ratio.HBV-DNA in 
serum was measured by dot blot hybridisation (14) .Liver biopsy 
samples were scored blindly according to the criteria of an 
international group (15). 
Patient compliance with interferon therapy was estimated by the 
reduction in blood leucocyte count.Acyclovir levels in serum 
were measured using a radioimmunoasssay as described by Quinn 
( 16). 
Differences between the populations were analysed using the non-
paired Wilcoxon test for continuous data and Fisher Exact test 
for discontinuous data. 
Results. 
The main characteristics of the 36 patients who participated in 
this trial are shown in table 1.There were no significant 
differences between treated patients and untreated controls on 
entry to the study. 
Effects. 
The effects of therapy are shown in figure 1-S.A significant 
decrease in markers of viral replication (HBeAg,HBV-DNA,DNA-p) 
was observed in treatment responders compared to non-responders 
and untreated control patients (p<0.01).Seven treated patients 
lost HBeAg (responders),but none of the 18 controls.Five of 
seven responders also developed antibodies to HBeAg.Two treated 
patients lost HBsAg,one of them developed antiHBs antibodies. 
In patients with HBe-seroconversion clinical improvement 
(admittedly a subjective but important criterium) was noticed,and 
liver function became normal.Histologic evaluation will be done 
after one year follow-up. 
An analysis of factors that discriminates responders to antiviral 
therapy from non-responders showed significantly lower DNA-
polymerase activity and serum HBV-DNA in responders (table 2). 
During therapy reduction of DNA-polymerase activity,HBV-DNA, 
HBeAg and HBsAg was observed in all treated patients.However only 
patients with initial low levels of DNA-polymerase activity and 
HBV-DNA accomplished HBeAg seroconversion (fig 2,3,4). 
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Table 1. FEATURES OF PATIENTS ON ENTRY TO THE STUDY 
DEMOGRAFIC DATA 
sex (m/f) 
age,yr 
country of origin: 
Western Europe 
Meditterranean 
Asia/Far East 
VIROLOGY 
HBsAg (titer) 
HBeAg (P/N ratio) 
DNA-p (P/N ratio) 
HBV-DNA (pg/ml) 
HIV antibodies 
LIVER 
cirrhosis 
varices 
SGOT:normal 
SGOT:1-2 x raised 
SGOT > 3 x raised 
* 
+ 
= SEM 
= mean. 
Therapy 
<n =18) 
18/0 
39.9+ (1.9)* 
17 
1 
0 
83602+ (23681)* 
13.9+ 
22.7+ 
676+ 
3 
5 
3 
4 
12 
2 
(1.3)* 
(7.7)* 
(228)* 
Control 
<n =18) 
14/4 
32.9+ 
13 
2 
3 
81055+ 
13.7+ 
48.8+ 
3267+ 
5 
5 
3 
6 
10 
2 
(3.0)* 
(43142)* 
(1.4)* 
(22.9)* 
(2014)* 
25 
15 
1-
:::2: 6 0 
a. 
I 
< 
z 
0 
2 
0.8 
0 8 
therapy 
.A. Control 
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16 
¢non responders 
24 32 
weeks 
•responders 
fig !.DNA-polymerase activity before, during and after treatment 
with interferon and descyclovir.Viral markers decreased in 
responders and non-responders, but responders had lower levels of 
viral markers at the start of therapy.Viral markers in control 
patients showed no change. 
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fig 2.Serum HBV-DNA before, during and after treatment with 
interferon and descyclovir.Viral markers decreased in responders 
and non-responders, but responders had lower levels of viral 
markers at the start of therapy. Viral markers in control 
patients showed no change. 
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fig 3.HBeAg before, during and after treatment with interferon 
and descyclovir. 
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fig 4.HBsAg before,during and after treatment with interferon and 
descyclovir. 
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Table 2. VIROLOGICAL PROFILE OF TREATED PATIENTS ON 
ENTRY TO THE STUDY 
Responders Non-Responders 
n = 7 n = 11 
HBsAg (titer) 977714+ 74622+ 
HBeAg (PIN ratio) 13.2+ 14.3 
DNA-p (P/N ratio) 9.4+ 31.1+ 
DNA-p PIN ratio < 3 4* 0* 
HBcAg (%) 18+ 38+ 
HBV-DNA <pg/ml) 135+ 1019+ 
HIV antibodies 2* 1* 
* number of patients 
+ mean 
n.s. not significant. 
p.value 
n.s. 
n.s. 
n.s. 
p<0.02 
n.s. 
p<O. OS 
n.s. 
1-
0 
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fig S.Aminotransferase-levels in patients with chronic hepatitis 
B before, during and after antiviral combination 
therapy.Elevation of SGOT occurred in the treatment group, 
without a difference between responders and non-responders. 
97 
Side Effects. 
In general therapy was tolerated well.The main side effects 
consisted of fatigue and malaise (often described as a flu like 
illness),transient leuco/trombopenia and loss of scalp hair. 
All side effects dissappeared after dose reduction or 
discontinuation of therapy.In one patient therapy was stopped 
because of severe fatigue after 14 weeks.In the majority of 
patients <n = 12) the dose of interferon and descyclovir was 
reduced till 50-75 percent of the original dose.In 5 patients no 
dose adjustment was required. 
Compliance. 
Acyclovir plasma levels measured 2-4 hours after ingestion varied 
between 20 and 40 umol/l.Only 2.9% (3/103) of the samples tested 
showed no acyclovir when this should have been present according 
to treatment schedule. 
All patients had marked leucopenia during interferon therapy. 
Discussion. 
This study is among the first randomized controlled trials that 
shows significantly increased HBe-seroconversion in treated 
patients compared to untreated control patients.The HBeAg 
seroconversion rate observed was about 40% above that of the 
control group. 
Review. 
Our initial trial performed in 1979 with leucocyte interferon for 
6 weeks (dosage now considered adequate were used for 4 weeks) 
showed no difference between therapy and control (17).Recently, 
preliminary reports were published on 8 controlled trials with 
lymphoblastoid or recombinant alpha-interferon;the duration of 
treatment was 3-6 months with dosage of 15-35 MU per week (18-
25).Seven trials did not show a significant difference for HBe-
seroconversion between treatment and control,although a 20 % 
higher HBe-seroconversion rate was observed with inferferon in 
several studies (18,21,23,24,25). 
The beneficial results of our recent controlled trial might be 
related to the use of the combination therapy,or be influenced 
by the selection of patients. 
To clear the hepatitis B virus an intact host defence system is 
thought to be of importance.Previous studies identified patients 
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with HIV antibody as non-responders to antiviral therapy.However 
details of their immune status were not presented.In our study 
three HIV antibody positive patients with apparantly normal 
immunity were treated;two responded with HBe-seroconversion. 
Immune reactivity rather than the presence of HIV antibodies may 
be important for a therapeutic response. 
Favourable prognostic factors regarding the outcome of therapy in 
our population were low values of serum HBV-DNA and low DNA-
polymerase activity.In patients with high levels of DNA-
polymerase activity or HBV-DNA activity only transient 
depression of viral markers was observed. 
The 80% HBe-seroconversion rate observed in our pilot study with 
interferon and intravenous acyclovir could not be confirmed in 
this study with the oral prodrug of acyclovir.A possible 
explanation could be the lower plasma level of acyclovir that 
was obtained with the oral produg compared to intravenous 
acyclovir.A large randomised study using the combination of 
interferon and intravenous acyclovir is in progress now. 
Our results justify an optimistic view regarding antiviral 
treatment of chronic hepatitis B patients.Special attention 
should be given to initial levels of viral replication for 
identification of patients who could benefit from current 
antiviral therapy. 
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Antiviral combination therapy for chronic hepatitis type B has 
been used in our hospital since 1983.In this report we present 
the long-term follow-up of patients treated with alpha-
lymphoblastoid interferon in combination with acyclovir or the 
oral prodrug descyclovir (Burroughs Wellcome 515). 
We have re-analyzed the outcome for two groups of patients,who 
were the subject of previous reports (1,2).From 1983-1984,in an 
uncontrolled pilot study 12 patients were treated with acyclovir, 
interferon or - if both drugs were unsuccesfull - a combination 
of both (study !).In 1985-1986 a randomized controlled study was 
performed in 36 patients comparing the combination of interferon 
and descyclovir to "no therapy". (study II) .Results are presented 
as of December 1987 after a follow-up of 1-4 years. 
Methods. 
Patients and treatment. 
Patients who participated in the studies all had active viral 
replication as shown by the presence of stable levels of HBsAg 
and HBeAg in the serum for at least six months. 
Exclusion criteria for experimental antiviral therapy were:age 
under 18 or above 65 years,alcohol or drug addiction, 
decompensated liver disease (ascites, encephalopathy, variceal 
bleeding),serious other diseases or recent immunosupppressive 
therapy.Patients with cirrhosis all belonged to group A according 
to the Child-Pugh classification.Patients who were positive for 
HIV antibodies could enter the trial if they belonged to class 1 
or 2 of the Walter Reed classification (3). 
Study I. 
Twelve patients entered this study.Six patients were given a 
4-week course of alpha-lymphoblastoid interferon (WellferonR), 
and in case of no HBe-seroconversion after a month without 
treatment,a 4-week course of acyclovir (ZoviraxR).The remaining 
six patients received acyclovir initially and non-responders 
subsequently interferon.Assignment to treatment schedule was 
determined by random numbers .Acyclovir was administered 
intravenously in a dose of 15 mg/kg in 0.5 1 of fluid twice 
daily.Interferon was given intramuscularly in a dose of 2.5 MU;m2 
once daily;the dose was adjusted downwards according to 
tolerance. 
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Seven patients with persisting active viral replication after two 
treatment courses received the combination treatment of 
interferon and acyclovir.Interferon was given for at least 8 
weeks at the maximum tolerable dose used in the first study. 
Acyclovir was started 2 days after interferon,when fever and 
malaise had subsided;the dose was also the same as that given in 
the first course (15 mg/kg twice daily).Acyclovir infusions were 
given on an outpatient basis;two patients living more than 20 
kilometers outside the hospital area did not complete the 
acyclovir part of the combination therapy.If no seroconversion 
had occurred after two months,the combination treatment was 
repeated in some patients.To suppress side effects of interferon 
therapy 500 mg paracetamol was given qid. 
Study II. 
Thirty-six patients were randomized in blocks of six to either 
combination therapy or control.Treatment patients received 
interferon (WellferonR) 5 MU once daily subcutaneously for 16 
weeks in combination with descyclovir 1 gram orally twice daily 
for 8-16 weeks (4);during the first three days of therapy 
patients received slow-release indomethacin 75 mg orally twice 
daily to suppress fever and the flu-like syndrome.Patients 
administered themselves interferon like diabetics insulin. 
Treatment was stopped if a HBeAg test was negative on two 
consecutive occasions (HBe-seroconversion) or if side effects 
were intolerable.Control patients received no treatment. 
Assessment and laboratory methodology. 
Before treatment,and 4-monthly thereafter,all patients completed 
a diary score concerning quality of life,symptoms and signs;the 
maximum score was 120 points (5).During therapy patients were 
tested weekly for HBeAg, SGOT, creatinin, leukocytes and 
granulocytes.After therapy had been stopped and in control 
patients,monitoring was done every four weeks.At each visit 
serum was prepared and stored for HBV-DNA analysis.HBsAg was 
measured by a standard radioimmunoassay (Abbott,Ill).HBeAg was 
measured by a radioimmunoassay (Abbott,Ill) in a constant serum 
dilution for each patient.The dilution was chosen so that 
pre-treatment sera showed a P/N ratio of approximately 12.A P/N 
ratio below 2,1 in undiluted serum was considered a negative 
test.DNA-polymerase activity was measured by the method of 
Howard as modified by Fang (6),and expressed as P/N ratios (cpm 
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patient sample/cpm negative control sample).HBV-DNA in serum was 
measured by dot blot hybridisation (7).All liver biopsy samples 
were scored blindly according to the criteria of an international 
group (8).Patient compliance with interferon therapy was 
estimated by the decrease in blood leukocyte count;acyclovir 
levels in serum were measured by a radioimmunoasssay as described 
by de Miranda (9).Differences between the populations were 
analysed by the non paired Wilcoxon test for continuous data and 
Fisher Exact test for non-continuous data. 
Both studies were approved by the Medical Ethics Committee's of 
the participating hospitals. 
Results. 
Table I shows general, biochemical, virological and histologic 
entry data for patients in both the pilot and controlled study.No 
significant differences were observed - for study II - between 
treated patients and control patients in demografic data,mode of 
transmission,activity of the liver disease,degree of active 
viral replication or liver histology.Patients in study II 
however were in comparison to study I more frequently young 
homosexuals with a shorter duration of HBs antigenemia,higher 
levels of viral replication and less liver cell inflammation. 
Virologic response rates are shown in table II.Re-evaluation of 
the data from the pilot study made us realize more clearly that 
during the development of the antiviral combination treatment 
program repeated courses of therapy had been used in several 
patients.Therefore we also related response to the number of 
antiviral treatment courses.HBe-seroconversion related to the 
number of courses of antiviral therapy is now estimated at 42% 
for interferon/acyclovir (5/12), 27% for interferon alone (3/11) 
and 18% for acyclovir alone (2/11).An example of a patient from 
study I who lost DNA-polymerase activity ,HBeAg ,HBV-DNA and 
HBsAg,is shown in figure 1. 
Long-term follow up showed HBs-seroconversion in 4 out of 10 
study I patients with HBe-seroconversion.Three of those 4 
patients developed antiHBe antibodies and subsequently antiHBs 
after HBs-seroconversion.AntiHBe antibodies were observed in 3 
out of 6 patients with isolated HBe-seroconversion.HBe-
reactivation was observed in two patients.Both patients had 
cirrhosis and did not develop antibodies to either HBeAg or HBsAg 
at any time,although one patient had no evidence of HBV-DNA and 
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Tab1e I: Entry features of patients 
Genera .I 
no of patients 
sex (male) 
age (yrs,mean) 
origin: West-Europe 
Mediterranean 
East Asia 
T.ransm.iss.ion 
bloodproducts 
medical profession 
homosexuai 
heterosexual 
tattoojiv drug abuse 
unknown 
V.iro.logy 
HBsAg positive (yrs,mean) 
HBsAg (titre,mean) 
HBeAg (P/N,mean) 
DNA-p (P/N,mean) 
HBV-DNA (pg/ml,mean) 
HBcAg in nuclei,% (mean) 
antiHIV,positive 
B.iocllem.ist:z:y 
SGOT (IU/l,mean;n < 30) 
Beta-2 microglobulin 
(mg/L,mean) 
.Liver h.ist:o.logy 
CPH/CAH mild 
CAH (moderate,severe) 
Cirrhosis 
not tested 
Study I 
12 
11 
43.6 
11 
0 
1 
1 
2 
4 
1 
0 
4 
6.0 
33360 
9.1 
14.3 
nt 
28 
nt 
115 
nt 
6 
2 
4 
0 
Study II 
treatment 
18 
18 
39.9 
17 
1 
0 
0 
3 
7 
2 
2 
4 
2.5 
83602 
14.8 
31.7 
676 
31 
3 
59 
2.0 
9 
4 
5 
0 
control 
18 
14 
32.9 
13 
2 
3 
3 
1 
10 
1 
0 
3 
3.0 
81055 
13.7 
45.5 
3267 
23 
5 
49 
2.5 
10 
1 
5 
2 
Table II: 
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Number of patients (percentage> with thera-
peutic responses after antiviral therapy in 
chronic hepatitis B. 
St:udy I St:udyii 
Therapy ACV IFN ACV/IFN DACV/IFN CONTROL 
.Response 
HBeAg(+), DNA-p(+) 8 73%) 6 60%) 2 29%) 10 55%) 11 61%) 
HBeAg(+), DNA-p(-) 1 9%) 1 10%) 0 0%) 1 5%) 7 39%) 
HBeAg(-), DNA-p(-) 2 18%) 3 30%) 5 71%) 7 40%) 0 0%) 
number of patients 11 (100%) 10 (100%) 7 (100%) 18 (100%) 18 (100%) 
ACV: acyclovir, IFN: interferon, ACV/IFN: combination of acyclovir and 
interferon, DACV/IFN: combination of descyclovir and interferon. 
HBeAg I 
(PIN ratio) 625 
125 
108 
cJ]v ACV 0 ACV 0 
IFN 
\ 
\ 
\ 
\ 
' \ 
DNA-P log HBsAg -l 
(P/N ratio) 
100 
90 
80 
70 
60 
\ 
so 
40 
30 
' \ 20 
10 
12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 
.....,..HBeAg 
weeks 
fig l.Repeated courses of antiviral therapy CACV, IFN, ACV/IFN) 
ultimately leading to successive clearance of DNA-polymerase 
activity, HBV-DNA, HBeAg, HBsAg and development of antibodies. 
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HBsAg in the serum for more than 1 year.Two of the 12 patients 
from study I never had any persistent effect on the virus 
replication after antiviral therapy. 
In study II seven of 18 treated patients cleared HBeAg in 
contrast to none of 18 control patients.No reactivation has been 
observed.Six of 7 responders developed antibodies to HBeAg.HBsAg 
clearance with development of antiHBs antibodies was observed in 
two of 7 responders.DNA-polymerase and HBV-DNA was not detectable 
at entry in 2 patients of both treatment and control group. 
During follow-up DNA-polymerase disappeared in 6 treated and 5 
control patients respectively,whereas HBV-DNA became undetectable 
in 5 treated and 2 control patients. 
In both studies transition from the state of active viral 
replication (HBe-positive) to the state of virus latency (HBe-
negative) was associated with clinical improvement as reflected 
by increasing diary score and decreasing biochemical 
abnormalities in SGOT. 
In study II histological evaluation was done at entry and 
repeated after 1 year in both treated patients and controls. 
Twenty-eight patients had paired liver biopsies (13 controls,15 
treated,5 responders,10 non-responders).In all 7 patients who 
cleared HBeAg and HBV-DNA,HBcAg could no longer be detected in 
the liver.Significant structural improvement however was not 
observed,since the degree of fibrosis remained similar. 
In study II analysis of factors that could predict response to 
antiviral therapy,showed low initial serum DNA-polymerase and 
HBV-DNA in responders.During therapy depression of DNA-
polymerase activity,HBV-DNA,HBeAg and HBsAg was observed in all 
treated patients.However only patients with initial low levels of 
DNA-polymerase activity and HBV-DNA had HBeAg seroconversion. 
Response was not related to anti-HIV status or sexual preference. 
No differences in mode of transmission,SGOT-levels or HLA 
turnover assessed by serum beta-2 microglobulin levels at entry 
could be shown. 
Also,a non-specific rise in SGOT-levels during therapy was not a 
prognostic factor for HBe-seroconversion.However a specific 
(monofasic spike during the 8-12th week of interferon therapy) 
rise in SGOT was observed in seven of 7 responders,while such a 
rise in SGOT occurred in 6/11 non-responders <p <0.001).The SGOT 
spike preceded HBeAg clearance in six out of seven responders. 
Figure 2 shows examples of specific and non-specific rises in 
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fig 2.In relation to HBe-seroconversion specific and non-specific 
rises in SGOT in the second part of treatment are shown in panel 
A and B respectively.The early rise in SGOT is probably a toxic 
effect of interferon. 
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serum transaminases. 
A lag time between the period of drug therapy and HBe-
seroconversion was observed freguently.In study II HBe-
seroconversion occurred twice during therapy but after therapy in 
five patients.In study I HBe-seroconversion was observed during 
therapy in five patients and after therapy in others. 
Discussion. 
Treatment with the combination of interferon/acyclovir or 
interferon/descyclovir showed HBe-seroconversion in more than 40% 
(12/25),whereas none of the untreated control patients lost HBeAg 
during the observation period.Treatment with a single drug was 
associated with a lower percentage of HBe-seroconversion (27% for 
interferon and 18% for acyclovir).These results suggests the 
enhanced efficacy of combination therapy,but proof can only be 
obtained in a randomized controlled study comparing single agent 
and combination therapy.The overall high HBe-seroconversion rate 
(10/12,83%) of study I is in all likelihood influenced by 
patient-selection and repeated courses of treatment.Other 
investigators have found that symptomatic patients with a high 
degree of liver cell inflammation are prone to HBe-seroconversion 
(lO>;also repeating a course of antiviral therapy can boost the 
percentage HBe-seroconversion (11). 
During long-term follow up (1-4 years) reactivation of hepatitis 
B virus replication occurred in two patients.One of them had no 
HBsAg detectable in the serum for more than 1 year.Both patients 
had macronodular cirrhosis and did not develop antibodies after 
clearance of HBeAg or HBsAg.These observations made clear,that 
the concept of cure from chronic viral hepatitis B can only be 
applied to patients with loss of HBsAg and HBeAg,development of 
antiHBe and antiHBs antibodies and absence of HBcAg and HBV-DNA 
in the liver. 
Long-term follow up also showed an unexpected high rate of HBs-
seroconversion in patients with loss of HBeAg (6/17,36%) 
confirming observations by others (12,13).Apparently liver cells 
containing the hepatitis B viral genome are being distroyed or 
synthesis of HBsAg stops by an undefined mechanism.Disappearance 
of HBsAg does not imply cure of chronic hepetitis B since both 
development of hepatocellular carcinoma and reactivation can 
occur. 
Virus clearance and HBe-seroconversion occurred mainly in 
patients with initial low levels of viral replication and most 
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often after therapy had been stopped.Clearance of the virus was 
usually accompanied by a spike-like rise in SGOT levels during 
the third month of treatment.These observations,also found by 
others (l2>,suggest that antiviral agents initially suppress 
viral replication,thereby allowing the host immune response to 
recover and to eliminate virally infected cells. 
HBe-seroconversion was associated with clinical and biochemical 
improvement in almost all patients which persisted during follow 
up.However we did not observe a significant improvement in liver 
histology 1 year after start of treatment.In 5 study II patients 
liver fibrosis had not been affected.These findings underline the 
concept that antiviral therapy should now be applied early in the 
course of chronic infection to prevent structural damage of the 
liver as well as to minimize the risk of viral integration. 
Who should be offered this rather expensive therapy? We studied a 
predominantly Westeuropean population with an adult life acquired 
HBV infection.We did not observe any relationship between 
therapeutic response and sexual preference,HIV status,SGOT levels 
and the histological stage of the liver disease.The only 
predictors of HBe-seroconversion were initially low levels of 
viral replication.We therefore think that such patients should 
be candidates for antiviral combination therapy,which holds 
promise - albeit small - of a cure of the HBV infection. 
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Since the loss of viral HBeAg and HBV-DNA from the blood has been 
associated with improvement in liver disease (1,2),elimination of 
the hepatitis B virus,and not immunosuppresion,has become the key 
to effective treatment of chronic hepatitis B virus infection 
(3).In a pilot study we found that a combination of alpha-
interferon and acyclovir could induce a state of virus latency 
(HBe-seroconversion with loss of HBV-DNA> in 4 out of 5 treated 
patients (4).To document the validity of these encouraging 
therapeutic results,we performed a randomized controlled study 
using the combination of alpha-lymphoblastoid interferon 
<Wellferon) and descyclovir,an oral prodrug of acyclovir (5).The 
aim of the controlled study was to determine whether combination 
therapy consisting of interferon with descyclovir induces virus 
latency as indicated by disappearance of HBeAg.In addition we 
wanted to assess whether the induced loss of HBeAg persists,how 
persistent absence of this marker correlates with absence of 
HBV-DNA and whether a change from active hepatitis B virus 
replication to a state of virus latency is associated with 
disappearance of the histological characteristics of hepatic 
inflammation.We have already reported on virus elimination and 
reactivation after 32 weeks of observation (6).This paper 
concerns the long-term efficacy of antiviral combination therapy 
with special emphasis on the results of serum virology and liver 
histology till 2 years of observation. 
Patients and Methods. 
Study design. 
Patients who participated in this study all had histologically 
proven chronic liver disease and showed active viral replication 
as indicated by the presence of HBsAg,HBeAg and HBV-DNA or DNA-
polymerase activity in serum.The main exclusion criteria were:age 
under 18 or above 65 years,recent alcohol or drug addiction, 
decompensated liver disease (ascites,encephalopathy,variceal 
bleeding),clinical or histological suspicion of concomitant non-A 
non-B hepatitis,other serious diseases including active 
concomitant viral infection (CMV,Delta or EBV> and recent (<1 
year before entry) antiviral or immunosuppressive therapy. 
Patients who were positive for HIV-antibodies were accepted if 
class I or II of the Walter Reed classification,which implies 
normal immune reactivity (?).Patients were randomized in blocks 
118 
of six either to undergo treatment or to be controls.During the 
16 weeks of therapy patients were monitored weekly;for patients 
who had completed therapy and untreated controls,follow up was 
monthly until one year after entrance into the study. 
Subsequently,treated patients were examined every three months 
until two years after entry into the study.Nine patients who were 
initially in the 'no treatment' group received alpha- interferon 
after one year of follow up.Follow up for these patients was 
identical to that for treated patients during the first year of 
the study.Key-point evaluation was performed after 4,8,12 and 24 
months of follow up (fig l.).All patients gave written informed 
consent to the trial.The study was approved by the Medical Ethics 
Committee of the participating hospitals. 
Therapy. 
Treated patients received 5 MU alpha-lymphoblastoid interferon 
(Wellferon) once daily subcutaneously for sixteen weeks in 
combination with 1 gram descyclovir twice daily orally for 8-16 
weeks;during the first three days of therapy all treated patients 
received 75 mg of indomethacin (Indocid RetardR) twice daily 
orally.Patients administered the interferon themselves, as 
diabetics do insulin.Treatment was stopped if the quantitative 
HBeAg test was negative twice or side effects were not tolerated. 
Control patients received no treatment during the first year of 
the study:subsequently they were offered 5 MU alpha-interferon 
(Wellferon) once daily subcutaneously for sixteen weeks 
(descyclovir was no longer available).During therapy patient sera 
were tested weekly to determine HBeAg,AST, creatinine,leucocyte 
and granulocyte levels.Sera from patients who had completed 
therapy and all control patients were assessed every four weeks 
for one year and then every three months <fig l).Each serum 
sample was prepared and stored at -20 °C for beta-2 
microglobulin and HBV-DNA analysis. 
Laboratory methods. 
HBsAg was measured using a standard radioimmunoassay <Abbott, 
North Chicago,Ill.l;HBeAg was measured using a radioimmunoassay 
(Abbott,North Chicago,Illl.For quantification,HBeAg was measured 
in a dilution of serum that was constant for each patient.This 
dilution was chosen such that pre treatment sera showed a P/N 
ratio (cpm patient sample/cpm negative control sample) of 
approximately 12 +/- 2.A P/N ratio below 2.1 in undiluted serum 
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was considered a negative result.DNA-polymerase activity was 
measured by the method of Howard,as modified by Fang,and was 
expressed as a P/N ratio (8).HBV-DNA in serum was measured by dot 
blot hybridisation (9).IgM anti-HBc was measured using a standard 
Elisa (Abbott,North Chicago,Ill.) 
At entry and after one year all patients were tested for the 
presence of IgM-CMV,IgM-EBV(VCA),HIV and Delta antibodies.A 
positive HIV enzyme immunoassay antibody test (Wellcozyme) was 
confirmed by Western blot analysis.Routine serum biochemical 
tests were done using automated techniques (Couiter,SMAC, 
Technicon, NY) .Serum beta-2 microglobulin concentrations were 
measured in duplicate with the commercially available beta-2 
microglobulin radioimmunoassay (Pharmacia Diagnostics AB,Uppsala, 
Sweden).In addition in all cases an ultrasound examination of the 
liver and oesophagogram according to Muller's procedure were 
performed to detect portal hypertension and to exclude patients 
with possible hepatocellular carcinoma.In the event of suspected 
oesophageal varices on the oesophagogram, gastroscopy was carried 
out for confirmation. 
Two liver biopsies were obtained from all patients at the 
beginning of the study and again one year later:one was snap 
frozen in liquid nitrogen for immunofluorescence studies,the 
other was processed for routine microscopy.Liver biopsies were 
taken by the percutaneous Tru-cut technique.To reduce risks and 
sampling error in patients clinically suspected of cirrhosis,the 
liver biopsies were obtained by laparoscopy.Liver biopsy 
specimens were graded (under code) by one pathologist (FJWtK) 
according to the criteria of an international group <10).Each 
biopsy received a score for:classification, fibrosis, portal 
infiltrate density,portal infiltrate penetration and HBc in 
hepatocyte nuclei.Classification ranged from 0-6 (0 = no or 
non-specific abnormalities, 1 = chronic persistent hepatitis, 2 = 
mild chronic active hepatitis, 3 = moderate chronic active 
hepatitis, 4 = severe chronic active hepatitis, 5 = probable 
cirrhosis, 6 = cirrhosis).Fibrosis ranged from 0-5 (0 = none,1 = 
extension from portal tracts, 2 = sporadic portoportal septa,3 = 
portoportal septa, 4 = broad fibrous bands distorted architecture 
,5 =two nodules surrounded by fibrous bands).Portal infiltrate 
density ranged from 0-3 (0 = none, 1 = mild, 2 = moderate, 3 
dense).Portal infiltrate penetration ranged from 0-3 <0 =none, 
1 =mild, 2 moderate, 3 =severe). 
HBcAg was expressed as the estimated percentage of nuclei 
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positive for HBcAg in the snap frozen specimen.In the event of 
insufficient frozen material the biopsy specimens were stained 
for core antigen by the peroxidase anti-peroxidase technique. 
Statistics. 
Group frequencies were compared by the chi-square test and group 
medians by the Wilcoxon-rank sum test.Laboratory features of 
patients before treatment and at last follow up were compared by 
the Wilcoxon sign test.All data were analysed according to the 
'intention to treat' principle. 
Results. 
The main characteristics of the 36 patients who participated in 
this trial are shown in table 1.There were no significant 
differences between treated patients and untreated controls at 
entry into the study>.All patients were followed for at least one 
year after randomization.One treated patient (non-responder) died 
of Kahler's disease in the second year of the study;one control 
patient and 3 treated patients (one responder,two non-responders) 
were lost to follow up in the second year of the study. 
Responses to combination therapy. 
Changes in HBeAg. 
At the end of therapy (16 weeks> 3 patients had responded,while 
in the interval between 16 and 32 weeks another 4 patients 
exhibited loss of HBeAg (fig 2a>.After one year of follow up 
HBeAg seroconversion had occurred in 0% of control patients (95 % 
confidence interval 0-18 %) and 39% of treated patients (95% 
confidence interval 20-60%).This result is statistically 
significant (p<O.Ol>.In the second year of the study one initial 
non-responder became HBeAg negative.Since no reactivation had 
occurred at two years,8/18 patients (44 % ;95 % confidence 
interval 22-69 %) were HBeAg negative after two years. 
Changes in DNA-polymerase activity. 
Table 2 shows the number of patients with a positive test for 
DNA-p at each evaluation point.Figure 2 displays the percentage 
of patients who lost DNA-polymerase activity.During the treatment 
period 7/18 (38%) treated patients and 1/18 (5%) control patients 
exhibited disappearance of DNA-polymerase activity (p<0.01).After 
32 weeks of observation reactivation had occurred in 3 treated 
patients all of whom were HBeAg positive;DNA-polymerase activity 
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Table 1. Pretreatment characteristics of the study groups. 
1\ge (yrs; nedian, range) 
Sex <% rrales) 
Hi:JnOsexual <n, %) 
Anti HIV-positive <n, %) 
Therapy 
(n=18) 
36 (23-64) 
100 
7 (39) 
3 (17) 
Control 
(n=18) 
33 (19-49) 
77 
10 (28) 
5 (28) 
---------------------------------------------------------------------------
AI:ea of origin 
W:stenl Eul:ope 
Mediterranean 
Asia/Far East 
AST: No:mal (n) 
1-2 x raised <n> 
> 3 x raised (n) 
17 
1 
0 
4 
12 
2 
Bilirubin (IJIOC>l/1, n < 12) 11 (5.5) 
IgG (g/1, nedian, range, n < 17) 14.1 (6.9-14.2) 
13 
2 
3 
6 
10 
2 
7 (3.9) 
16.3 (9.6-34.7) 
HBsAg (nedian titre,range) 10,000 (800-640,000> 20,000 (200-320,000) 
HBeAg (nedian PIN ratio,range) 12.3 (5. 7-25.6) 12.4 (2.5-26.8) 
J:NA-p (na:lian PIN ratio,range) 10.9 (1.1-139) 
HBV-J:NA (nedian pg/Illl,range) 233 (0-4,000) 
Liver biqlsy classification 
CPH/CAH (mild) 
CAH (m::x::ierate, severe> 
Cirrhosis 
Not tested 
Child-Pugh classification A 
O=so:I;:hageal varices 
9 
4 
5 
0 
18 
3 
13.9 (1.2-390) 
133 (0-26,700) 
10 
1 
5 
2 
18 
3 
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Table 2. Outcome of therapy for treated patients compared to 
untreated controls. 
Group 
Control 
Therapy 
Group 
Control 
Therapy 
Group 
Control 
Therapy 
Number of 
patients in 
follow-up 
18 
18 
Number of 
patients in 
folow-up 
18 
18 
Number of 
patients in 
follow-up 
18 
18 
Number of patients HBe-negative 
Entry 16 weeks 32 weeks 52 weeks 
0 
0 
0 
3 
0 
7 
0 
7 
Number of patients DNA-polymerase 
negative 
Entry 16 weeks 32 weeks 52 weeks 
2 
3 
3 
10 
3 
7 
7 
8 
Number of patients HBV-DNA negative 
Entry 16 weeks 
2 
1 
3 
9 
32 weeks 
3 
7 
52 weeks 
5 
7 
40 
30 
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fig 2.Loss of serum viral markers in treated patients compared 
to untreated control patients.(* 
significant). 
p < 0.01 ; ns not 
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in control patients remained stable.After one year of follow up 
one treated patient who initially exhibited reactivation again 
showed absence of DNA-polymerase activity.In four control 
patients DNA-polymerase activity had disappeared at one year.The 
difference between treated and untreated control patients at 32 
and 52 weeks was not statistically significant. 
Changes in HBV-DNA. 
After 16 weeks 8/18 (44%) treated patients cleared HBV-DNA 
compared to 1/18 (5%) control patients <p<0.01).After 32 weeks of 
observation reactivation was demonstrated in 3 treated patients; 
all three patients had failed to clear HBeAg.One patient,who had 
already cleared HBeAg,showed loss of HBV-DNA at 32 weeks.In one 
patient (HBeAg positive after treatment) HBV-DNA had disappeared 
from the serum at 32 weeks but reappeared at 52 weeks.Three 
control patients exhibited loss of HBV-DNA after 52 weeks of 
observation (table 3;fig 2).The difference between treated and 
untreated control patients at 32 and 52 weeks was not 
statistically significant. 
Loss of HBsAg and antibody development. 
At one year two responders who had become HBsAg-negative had 
developed approximately 75 IU/1 anti-HBs.Five of 7 responders had 
developed anti-HBe after one year of follow up.This result still 
applied after two years of follow up. 
Other virological tests. 
At entry one control patient had IgM-EBV<VCA) antibodies;after 
one year no such antibodies were found.No Delta or IgM-CMV 
antibodies were found . 
Follow up of control patients after one year. 
Of the 18 control patients,one was lost to follow up and 9 
control patients received alpha-interferon treatment 1 year 
after randomization.Three of the nine responded (HBeAg, HBV-DNA 
negative).The 8 control patients who were not treated after one 
year either refused treatment (n = 5) or were considered to have 
unstable disease (n = 3).Four of these patients became HBeAg, 
HBV-DNA negative.At two years 7/18 (39 %) control patients lost 
HBeAg with single alpha-interferon therapy in 9 patients. 
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fig 3.Results of paired liver histology for responders en 6), 
non-responders en= 10) and control patients en= 13). 
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Histology. 
Paired liver histology was available for 16 treated and 13 
control patients.Analysis at entry and during follow up within 
this group was performed.Paired results before therapy and at 
one year for the items classification,fibrosis,portal infiltrate 
density and penetration and HBcAg are shown in figure 3. 
Histological classification improved significantly in 50% of 
treated patients compared to 15% of control patients (p=0.05;95% 
confidence interval for the difference: 2.7 - 66.5%).Portal 
infiltrate density decreased significantly in 44% of treated 
patients compared to 8% of control patients (p = 0.03;95% 
confidence interval for the difference 7.2-64%).Penetration of 
portal infiltrate decreased significantly in 63% of treated 
patients compared to 15% of control patients (p = 0.01;95% 
confidence interval tor the difference 16-78%).Fibrosis did not 
change significantly.Among responding patients a significant 
decrease in HBcAg expression was observed (p = 0.03). 
Changes in liver enzymes. 
As shown in figure 4 AST levels in patients responding to 
therapy improved while levels in non-responders and untreated 
controls did not change.Improvement in liver enzymes did not 
reach statistical significance. 
Beta-2 microglobulin. 
Results of the beta-2 microglobulin assay have been described in 
detail elsewhere (ll).Pretreatment levels of beta-2 
microglobulin were elevated in 39 % of patients.Significant 
differences in beta-2 microglobulin between treated patients and 
untreated controls were observed after 4 and 8 weeks of treatment 
(p < 0.05) .Prior to and during therapy the mean elevation of 
beta-2 microglobulin was similar in responders (n = 7) and 
non-responders (n = 11). 
Because of the observations of Pignatelli (12) we also tested the 
serum of seven responders and eight non-responders after 3, 7, 
14, 21 and 28 days of treatment.Beta-2 microglobulin in 
responders showed a mean increase of 20, 99, 74, 82 and 52% at 3, 
7, 14, 21, 28 days,respectively.In non-responders the mean 
increase in beta-2 microglobulin was 177, 121, 133, 104, 82 
percent,respectively.Four of seven responders and six of eight 
non-responders showed a rise in beta-2 microglobulin at 2 weeks. 
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Table 3. Individual characteristic of patients responding to 
antiviral combination therapy 
Patient no. 8 14 29 36 201 205 212 
Sex (rn/f) m m m m m m m 
H:xrosexual (+/-) + + + 
HIV antilxxlies (+/-) + + 
AST (IU/1, n < 30) 34 84 81 133 88 18 41 
Bilirubin (J.lllOl/1, ll< 12) 8 16 9 12 6 6 13 
----------------------------------------------------------------------------
Liver Histology: 
Biopsy Class ( 0-6) 2 6 2 3 1 3 3 
Fibrosis (0-3) 2 5 3 2 1 2 2 
Portal infiltrate density (0-3) 2 2 1 2 2 2 3 
Portal infiltrate penetration (0-3) 1 2 1 1 1 2 2 
HBcAg (%) so 0 30 25 30 5 0 
Virology: 
HBsAg (titre.102) 64 32 64 256 640 16 8 
HBeAg (PIN ratio) 6.8 7.1 18.7 12.4 25.6 15.8 5.7 
(dilution) 25 0 25 125 25 0 0 
DNA-p::>lynerase (PIN ratio) 2.7 1.621.2 29.3 3.1 1.9 1.5 
HBV-DNA (pg/ml) 67 0 667 400 67 133 13 
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Characteristics of patients responding to combination therapy. 
Individual characteristics of patients responding to antiviral 
combination therapy are shown in table 3.In an earlier report we 
analysed factors that might determine the outcome (6).Responding 
patients differed from non-responding patients only in lower 
pretreatment levels of viral replication <HBV-DNA,DNA-
polymerase activity). 
Discussion. 
The principal aim of this randomized controlled study was to 
determine whether combination therapy consisting of alpha-
interferon and descyclovir induces virus latency,as indicated by 
the disappearance of HBeAg.Our results show that approximately 40 
% of patients responded to a schedule of alpha-interferon and 
descyclovir combination therapy.This result is statistically 
significant.At the time this study was designed no statistical 
difference had been shown in studies using alpha-interferon 
alone,since then this has been shown in a large study (13). 
Therefore the additional effect of descyclovir is probably 
small. 
None of the patients who exhibited loss of HBeAg underwent 
reactivation,while in all patients persistent absence of HBeAg 
correlated with persistent absence of HBV-DNA.In contrast 5 
patients with persistent HBe-antigenaemia but loss of HBV-DNA <n 
= 3) or DNA-polymerase activity (n = 2> after therapy exhibited 
reactivation.In our study a negative HBeAg-test on two successive 
occasions correlated with a persistent favourable outcome of 
antiviral combination therapy.Responding patients differed from 
non-responding patients only in lower pretreatment levels of 
viral replication (HBV-DNA,DNA-polymerase activity). 
If we analyse the HBeAg results after 2 years of follow up on the 
basis of the 'intention to treat' principle the difference at one 
year disappears: 8/18 treated patients (44 %) compared to 7/18 
(38%) control patients lost HBeAg.This observation can be 
explained partly by elective alpha-interferon treatment of 
control patients but is also due to changes in untreated control 
patients in the second year of the study.Whereas in most studies 
follow up ends after one year of observation,our observations 
strongly indicate the need for prolonged follow up to evaluate 
the real efficacy of antiviral therapy. 
A change from active hepatitis B virus replication to a state of 
virus latency was associated with disappearance of histological 
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characteristics of hepatic inflammation and loss of expression 
of HBcAg in the liver (fig 3>.An interesting finding of our study 
is the statistically significant improvement in liver histology 
for all treated patients compared to untreated control patients 
as far as portal infiltrate penetration and density are 
concerned.This resuit conflicts with the findings of Hoofnagle 
(14).In his study improvement in degree of inflammation and 
necrosis was observed in the one year follow up liver biopsy for 
responders and not for treated non-responders.Possible 
explanations for these differences are selection bias (29/36 
patients had paired liver biopsies in our study compared to 41/45 
in Hoofnagle's study> or our use of a more detailed histological 
grading system.Therapy-induced improvement in liver histology 
could be an important argument in support of treatment of 
patients with chronic HBV infection. 
In patients responding to antiviral combination therapy AST 
levels normalized;this did not reach statistical significance.One 
possible explanation is the inclusion of patients with normal 
pretreatment AST levels in this study (fig 4). 
At entry 1 non-responder and 2 control patients had IgM-antiHBc 
antibodies.After one year IgM-antiHBc antibodies had developed 
in 1 non-responder and had disappeared in one control 
patient.Both patients with IgM-antiHBc antibodies at one year 
were HBe- negative in the second year of the study. 
At entry to the study 8 patients had HIV antibodies.Two of 3 
treated HIV-positive patients responded while none of 5 control 
patients exhibited loss of HBeAg,HBV-DNA or DNA-polymerase 
activity.After one year HIV-antibodies had developed in one 
non-responder.The presence of HIV-antibodies was not related to 
the outcome of antiviral therapy. 
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Beta-2 rnicroglobulin is a low molecular weight (11.8 kD> protein 
that is found in low concentrations in serum, saliva and 
cerebrospinal fluid.Serum levels increase with age,possibly 
reflecting decreased renal clearance.Elevated beta-2 
microglobulin levels are found in patients with renal 
disorders,autoimmune diseases,various viral infections 
(including HIV) and lymphoproliferative diseases.Of the hepatic 
disorders beta-2 microglobulin was found to be elevated in 
chronic active hepatitis,chronic hepatitis type B,alcoholic 
liver disease and primary biliary cirrhosis but could not be used 
to discriminate between these diseases (1-7). 
In serum beta-2 rnicroglobulin oc~urs as a small protein,while in 
tissue it is present as part of an HLA class I glycoprotein. 
Expression of HLA antigens on the cell membrane depends on the 
presence of beta-2 microglobulin;the latter ensures that the 
three-dimensional configuration of the antigens is retained. 
Normal parenchymal liver cells do not express either HLA class I 
antigens or beta-2 microglobulin on their membranes.Recently 
however it was found that expression of HLA antigens in the liver 
of chronic hepatitis B patients coincided with the presence of 
cytotoxic T-cells in periportal infiltrates (8).It is postulated 
that hepatocytes infected with hepatitis B-virus are destroyed by 
these cytotoxic T-cells,which respond to the complex of viral 
antigens and HLA class I antigens on the hepatocyte cell 
membrane. 
Interferon has been shown to enhance the concentration of HLA 
class I antigens on the surface of infected cells.The therapeutic 
action of these proteins therefore may be related to an increased 
presentation of infected hepatocytes to the immune system. 
Recently a mean increase in serum beta-2 microglobulin levels was 
observed after two weeks of interferon therapy in patients who 
exhibited a loss of active viral replication as a result of this 
therapy (9).In a randomized controlled trial we studied the serum 
levels of beta-2 microglobulin as well as markers of viral 
replication and liver cell necrosis (SGOT) in 36 chronic HBe-
positive patients,l8 of whom received alpha-lymphoblastoid 
interferon and descyclovir (BW 515).We tried to relate these 
findings to initial data at the start of the study as well as the 
therapeutic response in an attempt to evaluate whether beta-2 
microglobulin could be of any use in identifying patients who are 
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likely to benefit from antiviral therapy. 
Patients and methods. 
Patients. 
Thirty-six patients who participated in a randomized controlled 
trial of antiviral combination therapy for chronic hepatitis type 
B were studied.In nearly all cases active viral replication was 
reflected by HBeAg,HBV-DNA and DNA-polymerase activity in serum 
(patients without DNA-polymerase activity had stable HBeAg levels 
for three months prior to the trial> .Patients who participated 
in this study had no history or signs of recent alcohol abuse, 
drug addiction or non-A non-B hepatitis. 
In addition those with decompensated liver disease (ascites, 
variceal bleeding,encephalopathy,hepatoma>,a malignancy (other 
than basocellular type skin cancer) within the past 5 years or 
impairment of renal function were excluded from this study.All 
patients were evaluated on day 0 with a standardized history, 
physical examination,laboratory investigations,esophagogram and 
liver biopsy.Randomization was done in blocks of six.In the 
treatment group,there were 18 males with a median age of 36 years 
(range 23-64 yrs).The control group consisted of 14 males and 4 
females with a median age of 33 years (19-49 yrs> .Ten controls 
and seven treated patients were homosexuals.All patients were 
tested for the presence of HIV antibodies by a commercially 
available ELISA (Wellcozyme>;positive results were confirmed by 
Western blotting.The HIV antibody-positive patients who 
participated in this trial ( 3 treated, 5 control> belonged to 
class I or II of the Walter Reed classification system which 
implies normal immunology (10).In addition all patients were 
tested for the presence of concomitant viral infections using IgM 
CMV,IgM EBV (VCA> and anti-HDV (delta) antibodies at the 
beginning and the end of the study. 
The study was approved by the Medical Ethics Committee of the 
participating hospitals and written informed consent was 
obtained. 
Study design and follow-up. 
Eighteen patients received 5 Megaunits of alpha-lymphoblastoid 
interferon (Wellferon> once daily by subcutaneous injectipn in 
combination with 1 gr of the oral prodrug of acyclovir, 
descyclovir (BW 515> twice daily,for sixteen weeks.Treated 
patients were instructed to maintain fluid intake above 2.0 
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1/day.Descyclovir was started three days after interferon 
therapy had commenced.Control patients did not receive any 
treatment.Treated patients were seen after three days and then 
weekly during treatment.Control patients and those who had 
completed the sixteen-week course of therapy were seen 
monthly.Blood was sampled at each visit for assessment of the 
haematological,biochemical and viral parameters;part of the 
serum was prepared and stored immediately at -2o·c for 
determination of beta-2 microglobulin.Treatment response was 
defined as absence of HBe antigen on two successive occasions 
with absence of serum HBV-DNA. 
In study A,we compared beta-2 microglobulin with entry 
features,liver biochemistry,liver histology and virology. 
In study B we determined beta-2 microglobulin,viral markers, 
SGOT,creatinine and creatinine clearance every 4 weeks and 
compared the results obtained for 18 treated and 18 untreated 
control patients. 
In addition,we compared these markers after 3,7,14,21,28 days of 
interferon therapy in 7 treatment responders and 8 non-
responders.(For 3 non-responders insufficient serum was 
available for testing.) 
Beta-2 Microglobulin assay. 
Serum beta-2 microglobulin concentrations were measured in 
duplicate with the commercially available beta-2 microglobulin 
radioimmunoassay (Pharmacia Diagnostics AB,Uppsala,Sweden).The 
assay was carried out according to the manufacturer's 
instructions.The mean and upper limits of normal<+ 2 SD) for 
serum beta-2 microglobulin levels for normal subjects under the 
age of 60 are 1.7 and 2.4 mg/1 and for subjects over the age of 
60 2.0 and 3.0 mg/l,respectively.The initial standard curve was 
repeated after 50% and 100% of the samples had been analyzed to 
test for trend.No trend was observed.Pooled serum samples were 
used to determine the intra-assay coefficient of variation.This 
coefficient equaled 6% when the beta-2 microglobulin 
concentration was 2.8 mg/1. 
Laboratory evaluation of the liver disease. 
HbeAg was measured by radioimmunoassay (Abbot,Ill,USA).DNA-
polymerase activity was measured by standard methodology as 
described by Fang (11).Results are expressed as a ratio of the 
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activity in patient serum to that in normal control serum.The 
serum amino-transferases,alkaline phosphatase,bilirubin,serum 
albumin and serum creatinine were measured in our clinical 
chemistry laboratory using an automated system (SMA-12). 
Immunological activity was indicated by the immunoglobulin G and 
smooth muscle autoantibody concentrations as well as the C1q 
binding activity.Liver biopsy samples were obtained from eighteen 
treated patients and sixteen controls.One sample was processed 
for routine histological determinations while the other was snap-
frozen in liquid nitrogen for immunofluorescence studies.The 
liver biopsy samples were scored blindly on the basis of the 
criteria established by an international group.Both the density 
and the penetration into liver tissue of the portal inflammatory 
infiltrate were scored on a scale of 0 to 3 (12). 
Statistical Analyses. 
Beta-2 microglobulin levels at entry to this study were analyzed 
in relation to age,HIV antibody status,immunological 
measurements,liver function and liver biopsy score using a 
multiple matrix plot and calculation of linear correlation. 
Significance was tested with a Spearman rank correlation 
test.Changes in beta-2 microglobulin levels in treated patients 
and controls were analyzed by the method of variance using age 
and HIV status as covariates.Differences in SGOT,DNA-polymerase 
and HBeAg levels were tested using a Mann Whitney U test for non-
paired samples.All statistical analyses were carried out with 
STATA (Computing Resource Center,Los Angeles,U.S.A.) on an 
Olivetti M24 personal computer. 
Results. 
Antiviral treatment. 
Baseline characteristics are shown in table !.No significant 
differences were observed between control patients,treatment 
responders and treatment non-responders with regard to age, sex, 
HIV status, histology, transaminase activity or IgG levels. 
Seven treated patients responded (seroconversion from the HBe-
positive to the HBe-negative state with absence of HBV-DNA) to 
therapy.Antibodies against HBe developed in five of these 
patients.No serum HBV-DNA could be detected in any of the seven 
responders after one year of follow-up.Liver histology after one 
year of follow-up showed clearance of HBcAg from the liver.In 
control patients HBe-seroconversion was not observed.The results 
Table I: Characteristics of patients participating in our studies. 
Control 
Number of patients (n) 18 
Age (years, median, range) 33 (19-49) 
Male/female (n) 14/4 
Homosexual (n, %) 10 (28) 
anti-HIV positive (n, %) 5 (28) 
IgG (g/1, median, range) 16,3 (9,6-34,7) 
SGOT (IU/1, median, range) 43 (12-161) 
Beta-2 microglobulin (mg/1, median, range) 2,4 (1,6-4,9 
Beta-2 microglobulin, mean increase. nt* 
(t = 2 weeks vs. t = 0 weeks; %, range) 
Cirrhosis (n, %) 5 (28) 
Therapy 
18 
36 (23-64) 
18/0 
7 (39) 
3 (17) 
14,1 (6,9-14,2) 
43 (18-133) 
1,8 (0,3-4,0) 
nt* 
5 (28) 
Responders 
7 
35 (23-64) 
7/0 
3 (43) 
2 (28) 
20,4 (6,9-26,2) 
81 (18-133) 
1,89 (1,5-2,4) 
+74% (-47 - +320) 
1 (14) 
Non-responders 
11 
42 (26-63) 
11/0 
4 (36) 
1 (9) 
12,6 (9,3-27,2) 
40 (22-127) 
1,6 (0,3-4,0) 
+133% (-19 - +294) 
4 (36) 
-+:>. 
-
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of antiviral treatment have been described in more detail 
elsewhere (13-15). 
Serum beta-2 microglobulin levels in chronic hepatitis type B. 
In study A,serum beta-2 microglobulin levels were elevated in 14 
of the 36 patients (39%). 
The initial levels of beta-2 microglobulin could not be related 
to hepatitis activity, as indicated by the SGOT levels (table 
!),nor was there a relation with alkaline phosphatase or 
bilirubin levels,liver histology or the penetration or density 
of the portal inflammatory infiltrate (table !!).There was no 
correlation between the levels of beta-2 microglobulin and either 
immuno-globulin-G concentrations or the presence of smooth 
muscle antibodies.Of the eight patients with HIV antibodies,four 
showed elevated beta-2 microglobulin levels (50%).Renal 
function, assessed by serum creatinine levels and creatinine 
clearance, was normal in all patients. 
Serum beta-2 microglobulin during treatment. 
In study B the beta-2 microglobulin serum levels at the start of 
therapy found for patients who responded to treatment 
(responders),patients who did not respond to treatment (non-
responders) and untreated control patients were comparable.During 
treatment mean beta-2 microglobulin levels rose in responders and 
non-responders,while the levels remained stable in untreated 
controls (fig.1).Significant differences were observed at week 4 
and week 8 between treated patients and control patients 
(p<0.05).No significant differences however were observed 
between responders and non-responders.Serum transaminases 
followed the same pattern with significant differences between 
treated and non-treated patients at week 4 and week 8 <p<0.05) 
but not between responders and non-responders.Renal function did 
not change significantly during therapy (p>0.10). 
Because of the observations of Pignatelli (9) we also tested the 
serum of seven responders and eight non-responders after 3,7, 
14,21 and 28 days of treatment.Beta-2 microglobulin in responders 
showed a mean increase of 20,99,74,82 and 52% at 3,7,14,21,28 
days,respectively.In non-responders the mean increase in beta-2 
microglobulin was 177,121,133,104,82 percent,respectively.Four of 
seven responders and six of eight non-responders showed a rise in 
beta-2 microglobulin at two weeks (fig.2). 
Table II: 
Histological 
Beta-2 microglobulin levels in relation to portal infiltrate and 
histological classification of liver biopsy. 
Infiltrate Infiltrate Beta-2 microglobulin (mgLl) 
classification Densitv Penetration 
n 0 1 2 3 0 1 2 3 range no. of patients > 2.4 
CPH 11 7 4 - - 8 3 - - 1.5 - 4.9 5 (45%) 
CAH 13 3 6 3 1 
- 9 4 - 1.3 - 5.0 4 ( 3 0%) 
Cirrhosis 10 2 8 - - - 5 5 - 0.3 - 2.8 5 (50%) 
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Discussion. 
Recent studies suggest possible therapeutic efficacy of long-term 
interferon therapy for chronic hepatitis B.However,HBe-
seroconversion with development of antibodies occurred in only a 
minority of the treated patients (16-21).Early identification of 
patients who could benefit from treatment is therefore 
important.Various factors related to the outcome of treatment 
have been proposed retrospectively:oriental race,positive HIV 
antibody status and homosexuality are characteristics of those 
who show little response whereas an elevated SGOT level or a 
histology compatible with chronic active hepatitis is said to 
identify patients who could benefit from treatment (22).In a 
matched controlled study a mean increase in beta-2 microglobulin 
after 14 days of interferon therapy was reported to be indicative 
of a favorable response to therapy,the mechanism being enhanced 
expression of HLA class I antigens leading to increased 
presentation of infected hepatocytes to the immune system (9). 
Our study indeed showed a mean increase in beta-2 microglobulin 
levels in patients during interferon therapy.This rise in beta-2 
microglobulin could not be explained by age or HIV status because 
both were used as covariates in our analysis,nor could it be 
attributed to either decreased renal tubular function related to 
descyclovir therapy or other viral infections (23).Possibly 
concomitant cell lysis induced by interferon after 4 weeks of 
therapy can explain the rise in beta-2 microglobulin after 4 
weeks.However,elevation of beta-2 microglobulin in our studies 
was not related to imminent HBe-seroconversion,but probably 
reflects interferon-induced hepatitis.Lok also found interferon 
therapy-related hepatitis (16).Beta-2 microglobulin levels after 
two weeks of interferon therapy increase in 73% of patients 
without discrimination between responders and non-responders 
(fig.2). 
we conclude therefore that exogenous alpha-lymphoblastoid 
interferon increases serum levels of beta-2 microglobulin, 
possibly by enhanced HLA class I expression.However we could not 
distinguish responders from non-responders by means of beta-2 
microglobulin serum levels alone,even if assessed in the first 4 
weeks of therapy before SGOT rises. 
In the complex interaction between the virus,the host and the 
antiviral agent beta-2 microglobulin reflects HLA antigen 
expression.We could not use beta-2 microglobulin alone for the 
selection of individual patients for antiviral therapy but it may 
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be of use in a multifactorial model which describes this 
interaction. 
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Chapter 9. 
Improvement of hepatitis B associated g1omerulonephritis after 
treatment with antiviral combination therapy. 
The contents of this chapter have been published in the Journal 
of Hepatology 1989;8:367-372, under the same title with the 
following authors: R.A.de Man, S.W.Schalm, A.J.van der Heijden, 
F.J.W.ten Kate, E.D.Wolff, R.A.Heijtink. 

Chapter 9. 
Introduction. 
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Infection with the hepatitis B virus can be associated with 
extrahepatic manifestations such as polyarthralgia,skin lesions 
(Gianotti-Crosti syndrome>,polyarteritis nodosa and certain 
types of glomerulopathy,all of which are thought to be immune 
complex-mediated (1,2).In patients with hepatitis B-related 
glomerulonephritis,gross proteinuria is related to the presence 
of the viral HBe-antigen in the blood (3).The important role of 
HBe-immune complexes in the pathogenesis of kidney disease is 
often emphasized (4).Improvement of kidney disease after 
spontaneous clearance of the virus has been described although 
favorable effects of antiviral therapy in hepatitis-B associated 
glomerulonephritis have also been reported (5,6,7,8).In four 
patients the nephrotic syndrome disappeared after antiviral 
therapy.Relapse of the nephrotic syndrome was associated with 
persistence of the HBe-antigen.The present report concerns a 
patient with a progressive nephrotic syndrome associated with 
active hepatitis B virus replication for a period of at least 
four years and deposition of HBc and HBe-immune complexes in the 
kidney;antiviral combination therapy induced virus latency, 
followed by disappearance of the nephrotic syndrome. 
Materials and methods. 
Hematology and routine chemistry were determined by the 
autoanalyzer using standard methods.HBsAg was measured using a 
standard radioimmunoassay (Abbott,Ill>.HBeAg was measured by 
radioimmunoassay (Abbott,Ill> in a constant serum dilution.This 
dilution was chosen such that a P/N ratio of approximately 12 +/-
2 would be obtained in pretreatment sera.A P/N ratio of less 
than 2.1 in undiluted serum was considered HBeAg negative. 
DNA-polymerase activity was measured by the method of Howard as 
modified by Fang (9).Results were expressed as P/N ratios (cpm 
patient sample/cpm negative control sample).HBV-DNA in serum was 
measured by dot blot hybridization (10).Liver and kidney 
immunofluorescence studies for detection of viral antigens were 
performed using monoclonal antibodies (anti-HBe antibody courtesy 
of Prof.H.C.Thomas;anti-HBs,anti-HBc antibody courtesy of 
Organon,Oss) .The specificities of the antiHBs,anti-HBc and 
anti-HBe monoclonal antibodies were confirmed with separate 
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Pre treatment observation 
Anti HBe(i) 
.. 
Post treatment 
observation 
fig 1.Stable pretreatment markers of hepatitis B-associated 
nephrotic syndrome, improving after therapy-induced HBe-
seroconversion.Note the sequence of events after start of 
treatment: drop in HBV-DNA and HBeAg, rise in SGOT and subsequent 
rise in serum total protein.Apparently treatment induces 
suppression of virus DNA and protein synthesis, allowing recovery 
of immune response with clearance of virally infected 
hepatocytes. 
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positive and negative control slides.All biopsies were scored 
according to the criteria of an international group (11,12). 
Case report. 
A boy born in 1976 on the Cape Verde Islands came to the 
Netherlands in 1982.In that year he visited the Children's 
Hospital because of scrotal swelling.Nephrotic syndrome with 
generalized edema,hypertension (RR 130/80),hypoproteinemia (38 
g/l,normal 62-75 g/l),hypocomplementemia (C1q 0.09 g/l,normal 
0.14-0.26 g/1; C3 0.7 g/1, normal 0.9-1.6 g/1; C4 0.11 g/1, 
normal 0.17-0.37 g/1; CHSO 50 %,normal 80-155%),microscopic 
erythrocyturia and proteinuria (9 g/1) was diagnosed.A kidney 
biopsy showed membranous glomerulonephritis with deposition of 
immune complexes.Subsequently his serum was found to contain 
HBsAg (titer> 1:10.000),HBeAg,HBV-DNA and DNA-polymerase 
activity.His mother was HBsAg positive and HBeAg negative 
without antibodies to HBe.The nephrotic syndrome continued for 
four years.In total twelve hospital admissions took place 
because of exacerbation of the nephrotic syndrome and the need 
for albumin infusions.Anti-hypertensive treatment was started in 
1985 with hydrochlorthiazide,dihydralazine and propanolol. 
Hepatitis B markers showed stable active viral replication during 
this four-year period <fig 1.).In May 1986 the patient underwent 
renewed assessment because antiviral combination therapy was 
being considered.Clinical problems included fatigue which,in 
combination with the frequent hospitalization,had impaired his 
psychosocial development.On physical examination he was found to 
have generalized edema; there were no cutaneous signs of chronic 
liver disease.Blood pressure was 100/70 mm Hg (with therapy). 
Laboratory studies yielded the following data: blood urea 
nitrogen 9.3 mmol/1 (normal 3.3-5.6 mmol/l),creatinine 42 umol/1 
(normal 50-90 umol/l),total serum protein 32 g/1 and albumin 
below 9%.Bilirubin was below 5 umol/1 <normal below 9 umol/1), 
AST was 23 IU/L,ALT was 29 IU/L (AST/ALT normally below 30 
IU/L).The urinary sediment showed microscopic erythrocyturia and 
gross proteinuria which equaled 13.8 g/l.Corrected creatinine 
clearance was 67 ml/min <normal for age and body surface).Further 
immunologic evaluation revealed low serum levels of C1q (0.07 
g/l),C3 (0.51 g/l),C4 (0.14 g/1) and CHSO (53%).Serum IgG was 
fig 2. Electron microscopy of kidney before treatment showing -HBc like particles along the 
glomerular basement membrane (left panel, overview EM 7000x; middle panel EM 50.000x). 
After therapy-induced HBe-seroconversion only an amorphous protein-like substance persists 
(right panel EM 50.000x). 
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5.55 g/1 (normal 7.5-16.0 g/l).HBsAg was positive (titer > 
1:10.000>,HBeAg was positive (P/N ratio 14.6,dilution 
1:5),DNA-polymerase activity was strongly positive (P/N ratio 
77.1) and the HBV-DNA level in serum was 50 pg/ml.An esophagus 
X-ray showed no signs of esophageal varices.Liver histology 
demonstrated chronic persistent hepatitis,with positive 
immunofluorescence for HBsAg,HBcAg (80% hepatocyte nuclei> and 
HBeAg.A kidney biopsy taken before treatment revealed membranous 
glomerulonephritis with spikes (Churg type III> and extensive 
granular deposits of IgG,C3,C1q,HBcAg and HBeAg along the 
glomerular basement membrane.HBsAg was absent.Electron 
microscopy of the kidney showed virus-like particles resembling 
HBcAg along the basement membrane (fig 2>.After approval of our 
treatment protocol by the Medical_Ethics Committee and the boy's 
parents,he was given 2.5 Megaunits alpha-lymphoblastoid 
interferon (Wellferon> subcutaneously once daily for 10 weeks and 
450 mg of intravenous acyclovir twice daily for the first two 
weeks.Therapy proceeded without complications.In the 8th week,a 
severe hepatitis (ALT 30x upper limit of normal> developed 
without evidence of hepatic decompensation (normal bilirubin, 
normal clotting factors).HBeAg became negative in the 8th week; 
therapy was stopped after 10 weeks.Antibodies against HBe 
developed while HBsAg (titer 1:8) persisted.No HBV-DNA could be 
detected in serum after HBe-seroconversion had occurred.The 
nephrotic syndrome disappeared after HBe-seroconversion. 
Reevaluation one year after treatment showed marked clinical 
improvement with disappearance of edema,hypoproteinemia and 
hypocomplementemia.The antihypertensive treatment had been 
discontinued.In the urine microscopic erythrocyturia had 
disapppeared while slight proteinuria (serum protein 60 
gr/l,proteinuria 1- 2 gr/l/24h> remained.A kidney biopsy still 
showed membranous glomerulonephritis <Churg type III> with mild 
mesangial cell proliferation,and immunofluorescence indicated 
granular deposits of IgG (mainly IgG subclass four),C3 and C1q 
along the basement membrane.HBsAg,HBcAg and HBeAg were absent. 
Electron microscopy did not reveal any virus-like particles.In 
the blood a state of virus latency (HBsAg positive: titer 1:8, 
HBeAg/HBV-DNA negative,antiHBe positive> had developed.In the 
liver a minimal portal infiltrate persisted,without piecemeal 
necrosis or ground glass cells.No HBcAg,HBeAg or ground glass 
fig 3. Pretreatment liver and kidney biopsies showing minimal chronic persistent hepatitis (left 
panel, LM 150x), membranous glomerulonephritis with extensive IgG deposits (middle and right 
panel, LM 380x). 
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cells could be detected by immunofluorescence; membrane-bound 
HBsAg remained present in low quantities. 
Discussion. 
We have described a patient who suffered from a hepatitis B-
related membranous glomerulonephritis.Pretreatment observation 
during a four-year period showed a stable nephrotic syndrome with 
markers of active viral replication in the blood but no signs of 
hepatitis activity.Antiviral treatment induced a state of virus 
latency reflected by clearance from the blood of HBeAg,HBV-DNA 
and DNA-polymerase and development of antiHBe antibodies. 
Induction of virus latency was associated with an immediate 
improvement in the clinical condition of the patient and 
disappearance of the nephrotic syndrome.Complement levels in 
serum became normal and anti-nypertensive treatment could be 
stopped.The liver and kidney biopsies showed clearance of viral 
antigens,although appreciable kidney damage remained. 
Hepatitis B associated glomerulopathy in children occurs 
predominantly in boys.The morphologic lesion is usually 
membranous glomerulonephritis (3,16) but IgA nephropathy,a mixed 
form between IgA nephropathy and membranoproliferative 
glomerulonephritis,and mesangioproliferative glomerulonephritis 
also appear to be associated with hepatitis B markers (13,14). 
Associated liver histology can be chronic active hepatitis but 
chronic persistent hepatitis and liver cirrhosis have also been 
described (15).0ur patient presented with extensive granular 
immune complex deposits,containing HBcAg,HBeAg but not HBsAg, 
along the glomerular capillary wall.Electron microscopy showed 
core-like particles within the basement membrane and in the 
subendothelial space.The deposition of HBsAg,HBeAg and HBcAg has 
been described previously (4,13,15,17),but the specificity of the 
polyclonal antibodies used in the studies has been questioned 
(18).If the deposits in the kidney are related to particle size, 
one would expect HBeAg deposits.At blood pH both HBsAg and HBeAg 
have a net negative charge which may favor deposition along the 
glomerular basement membrane. 
HBeAg is present in the blood in two forms,the smaller form 
having a molecular weight of 19,000 D and the larger a molecular 
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weight of 300,000 D; the latter consists of circulating 
HBeAg-immune globulin complexes (4).During the stage of active 
viral replication HBeAg is present in excess and both forms can 
precipitate on the basement membrane.In a state of virus latency 
the continuous influx of antigen stops and the kidney can clear 
antigens already precipitated.In our patient,as in other 
studies,HBcAg was also demonstrated by immunofluorescence while 
electron microscopy showed core-like particles (13).Primary 
deposits of HBeAg may have induced structural changes with 
increased permeability paving the way for the deposition of 
HBcAg.After HBeAg seroconversion and disappearance of the viral 
markers from the kidney,residual damage to the kidney was still 
found to be marked.Partly,the damage must be structural since it 
is attributable to a chronic infection of several years duration; 
however inflammation with immune deposits has persisted, even 
after the disappearance of viral antigens.In the animal model 
renal tubular antigens have been identified in immune deposits 
along glomerular capillary walls (19).Possibly deposition of 
hepatitis B antigens initiated the kidney inflammation with 
exposure of kidney antigens ultimately leading to postinfectious 
glomerulonephritis. 
Was antiviral therapy successful in curing the nephrotic syndrome 
or have we just observed a spontaneous remission? Marked 
proteinuria appears to be associated with the presence of HBsAg 
and HBeAg in serum (3,20>.Improvement of the kidney disease 
after spontaneous clearance of the virus has been described (5). 
Our pretreatment observation data with quantitative hepatitis B 
virology and histologic documentation of the disease over a 4-
year period point to unabating virus replication until the start 
of treatment and therefore make spontaneous seroconversion highly 
unlikely. 
We treated our patient because conservative therapy failed and 
frequent hospitalization was hampering his psychosocial 
development.Should all of our patients with hepatitis B-
associated membranous glomerulonephritis now undergo experimental 
antiviral combination therapy? We believe this approach should be 
reserved for HBeAg-positive patients who are not likely to 
undergo spontaneous seroconversion with an associated remission 
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of their nephrotic syndrome.The incidence of spontaneous 
remission of nephrotic syndrome drops after approximately one 
year of observation (20).We suggest a kidney biopsy for 
detection of viral antigen and/or particles by immunofluorescence 
and electron microscopy after an observation period of one year. 
If strong evidence for viral-induced disease is present antiviral 
combination therapy should be considered since,at that time,the 
chance of spontaneous remission is low and marked post-infectious 
damage usually has not yet occurred. 
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The studies described in this thesis focussed on a combination of 
acyclovir and alpha-lymphoblastoid interferon for treatment of 
chronic HBV infection.In this chapter results obtained with other 
combination therapies will be discussed.Using the new information 
that has evolved from our clinical research as well as that 
reported in the literature, I will try to predict future 
strategies for antiviral therapy.The model aims at a 
differential approach to antiviral treatment for the various 
categories of cases, since it is likely that the pathobiology of 
HBV-induced liver damage differs between these categories. 
Combination therapy. 
Combination of single drugs in order to improve the results 
obtained with alpha-interferon, nucleoside analogues or 
corticosteroids alone seems to be a rational approach.A problem 
is the selection of the drugs to be included in a combination 
therapy.What is more important: more profound suppression of 
viral replication than can be achieved with alpha-interferon 
alone,or enhancement of the immune response ? Nucleoside 
analogues suppress viral replication, but may also suppress 
immune reactivity.Prednisone withdrawal enhances immune 
reactivity,but may also increase viral replication.Nearly all 
combinations have been tested in the last 5 years. 
Alpha-interferon + adenine arabinoside. 
The combination of alpha-interferon with the nucleoside analogue 
adenine arabinoside or its monophosphate derivative has been 
evaluated by the Stanford group in two open studies and one 
large randomized double-blind placebo-controlled trial (1-4).In 
the first open study sixteen patients received ARA-A 
intravenously (5-15 mg/kg/day) for 7-14 days at intervals of four 
to six weeks in combination with 2.5-7.5 MU leucocyte alpha-
interferon daily.Later in the trial interferon was given in 14-
day cycles of a dose of 5 MU daily overlapping with the last 5 
days of ARA-A therapy.Six of sixteen patients had received prior 
antiviral therapy.HBe-seroconversion occurred in 7!16 (43%> 
patients;one patient became HBsAg negative.From this pilot study 
it was concluded that combination therapy increases the 
therapeutic response to ARA-A but also severely enhances ARA-A 
toxicity. 
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In the second open study ten patients were treated with ARA-AMP 
in combination with alpha-interferon as out-patients.The purpose 
of this study was to evaluate regimens that could be used in a 
larger controlled study.Three regimens were evaluated in a 
non-randomized fashion: 
a.7-day cycles of 5 mg/kg ARA-AMP alternating with 5 MU alpha-
interferon daily,starting with ARA-AMP and lasting 28 days for a 
total of four courses. 
b.28-day cycles of 5 mg/kg ARA-AMP alternating with 5 MU alpha-
interferon daily for 28 days for a total of three courses. 
c.28-day cycles of 7.5 mg/kg ARA-AMP alternating with 5 MU 
alpha-interferon daily for 28 days for a total of three courses. 
The most important finding of this study was patient non-
compliance for scheme 'c' because of severe ARA-A toxicity.One 
patient of the first group 'a' became HBeAg negative. 
The randomized placebo-controlled trial evaluated the efficacy 
of sequential courses of ARA-AMP with or without sequential 
courses of human leucocyte interferon (table 1).The study was 
severely compromised by toxicity problems:enrollment in the 
group receiving ARA-AMP sequentially with human leucocyte 
interferon had to be stopped because of painful paraesthesias of 
the legs.The study could not show any significant therapeutic 
effect of either regimens compared to placebo-treated controls.In 
conclusion,it was shown that alternating regimens of interferon 
and ARA-AMP are associated with significant toxicity and that 
repeated ARA-AMP cycles had no demonstrable effect,as had been 
suggested by other studies <5>. 
Corticosteroid withdrawal + ARA-AMP. 
In a pilot study Perillo treated 11 patients with prednisone (40 
mg/day tapered off to zero over 8 weeks> followed by a 4-week 
rest interval and a single 28-day cycle of ARA-AMP (6).ARA-AMP 
therapy consisted of intramuscular injections of 10 mg/kg twice 
daily for the first 5 days followed by 5 mg/kg twice daily for 
the next 23 days.The majority of patients participating were 
non-responders to a single course of ARA-AMP <n = 7) one year 
before.Five of 11 patients (45%) exhibited a loss of HBeAg and 
DNA-polymerase activity.Side effects during steroid withdrawal 
did not occur. 
A randomized controlled trial was performed by Yokosuka (table 1) 
(7).The response of patients on prednisolone withdrawal or a 
single course of ARA-A was comparable to that found for untreated 
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Table 1. AntiviJ::al cx:uhinaticn 1:herapy,:r::arrl:mized ccntJ:.oll.ed trials. 
.Author trial design trea:tnent p:ttients Seroconversion 
(reference) schedule (n) HBe(n) (HBe(%) 
Perillo (9) prednisolone 60 :rrq/d, 2 v;eeks 18 8 44 
40 :rrq/d, 2 v;eeks 
20 :rrq/d, 2 v;eeks 
0 :rrq/d, 2 v;eeks 
follov;a:i by 
rec.alpfa 2 b. 5 MU,once daily 
interferon 90 days 
no therapy 21 4 19 
Yokosuka ( 7) prednisolone 40 :rrq/d, 4 v;eeks 14 3 21 
prednisolone 40 :rrq/d, 4 v;eeks 
follov;a:i by 0 :rrq/d, 2 v;eeks 
ARA-A iv. 10 :rrq/d, 4 v;eeks 5 
10 :rrq,:d, 8 v;eeks 4 6 67 
ARA-A iv. 10 :rrq/d, 4 v;eeks 7 
10 :rrq/d, 8 v;eeks 3 1 10 
a:>ntJ:.ol no therapy 10 2 20 
Garcia (4) ARA-AMP im. 2.5 :rrq/kg, twice 13 3 23 
daily ,28 days. 
alternated 
with Cantell 5 MU, twice daily 
interferon sc. daily 28 days, 
for six IIOnths. 
ARA-.AMP im. 2.5 :rrq/kg, twice 24 1 4 
daily 28 days. 
alternated with 
a.1bmtin im/sc. daily 28 days. 
for six IIOnths. 
a.1bmtin im/sc. 0.5 cc. 27 5 19 
alternated with twice daily 
saline im for 
six IIOnths • 
[B Man (10) lymfoblastoid 5 MU, once daily 18 7 39 
al};tla.-interferon 16 v;eeks 
descyclovir 2 g daily 
no therapy 18 0 0 
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controls (HBe-seroconversion about 20 %), in contrast patients 
treated with prednisolone withdrawal followed by a single course 
of ARA-A responded with 67 % HBe-seroconversion.Although the 
numbers were small this study confirmed the lack of efficacy of 
prednisolone withdrawal therapy alone,whereas the combination 
with a nucleoside analogue may have influenced the response 
favourably.A large controlled study comparing corticosteroid 
withdrawal and ARA-AMP with ARA-AMP alone was never performed, 
probably because ARA-AMP became unavailable after toxicity 
reports in the USA study. 
Corticosteroid withdrawal + alpha-interferon. 
In one small uncontrolled study of 5 patients treatment with 
steroids followed by alpha-interferon led to HBe-seroconversion 
in three patients (8).The logical follow-up to this initial study 
on steroid withdrawal was a small randomized controlled study on 
the combination of steroid withdrawal and alpha-interferon 
(table 1) (9).This study included only asymptomatic patients with 
preserved hepatic synthetic function and normal haematological 
indices.The study could not prove a significant effect on HBe-
seroconversion although the number of patients who became HBV-DNA 
(9/18 vs. 3/21) and HBsAg (4/18 vs. 0/21) negative was higher in 
the treatment group.Possibly because of careful patient selection 
no hepatic decompensation was observed.Whether this treatment 
approach is superior to single drug therapy with alpha-
interferon has to be proven by large comparative studies,that 
are now in progress. 
Meta-analysis of antiviral combination therapy. 
Meta-analysis of the four published randomized controlled trials 
on various forms of combination therapy is shown in table 2.For 
all individual studies,the odds ratio for HBeAg seroconversion 
was calculated with its 95 % confidence interval.Stratified 
exact analysis was done by the classic Mantel-Haenszel method. 
The overall odds ratio for HBeAg seroconversion is estimated at 
4.1 (95 % confidence interva1:1.67 - 10.61) <p < 0.001) for 
combination therapy.No heterogeneity between the studies was 
shown <p = 0.164).In figure 1 the individual contributions of the 
studies to the overall efficacy of antiviral combination therapy 
are shown.In figure 2 the results of meta-analysis of combination 
therapy are compared with the results of meta-analysis of single 
drug therapy.Combination therapy seems to be superior to single 
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Table 2. Antiviral combination therapy:meta-analysis of HBe-
seroconversion in 4 randomized controlled trials 
Author odds ratio 95% confidence Bar no. 
(reference) interval for (fig 1) 
odds ratio 
Perillo ( 9) 3.29 0.67- 19.06 1 
Yokosuka ( 7) 7.03 0. 73-111.81 2 
Garcia (4) 1.31 0.17- 8.40 3 
De Man (10) 1.000 1.85-1000 4 
All studies 4.1 1.67- 10.61 5 
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fig l.Therapeutic efficacy (HBe-seroconversion> in 4 individual 
studies on antiviral combination therapy,and estimated 'overall' 
efficacy.Odds ratios are expressed as 95 % confidence limits. 
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fig 2.Estimated overall efficacy (HBe-seroconversion) of 4 
treatment regimens for chronic hepatitis type B.Each bar 
represents the odds ratio with 95 % confidence limits.Number of 
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Table 3. Antiviral therapy:summary of meta-analysis of randomized 
controlled trials. 
Treatment 
Combination therapy 
Alpha-interferon 
ARA-A/ARA-AMP 
Acyclovir 
patients 
treated (n) 
58 
262 
118 
26 
odds ratio 
4.10 
3.59 
2.37 
1.38 
95% confidence 
interval for 
odds ratio 
1. 67-10.61 
1.94- 6.92 
1.12- 5.19 
0.32- 6.46 
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drug treatment with acyclovir or ARA-A(MP).Meta-analysis suggests 
combination therapy to be somewhat better to single drug 
treatment with alpha-interferon,but the differences are small 
and the confidence intervals clearly overlap <figure 2,table 
3).In conclusion the therapeutic result with combination therapy 
has not come up to expectations compared to the result obtained 
with alpha-interferon alone. 
A differential approach to antiviral therapy for chronic HBV 
infection. 
Current approaches to antiviral therapy for chronic HBV infection 
have been aimed at developing one treatment strategy for the cure 
of all infected patients.However if we study specific groups of 
HBV infected patients it will probably appear that the mechanism 
by which HBV has caused the disease differs between them.To 
illustrate this,the pathobiology of chronic HBV infection in 
patients with a 'normal' immune response, immune-compromised 
patients and patients with immune complex-mediated disease,will 
be described.Subsequently data which are not sufficiently 
explained by the classical hypothesis for HBV-induced liver cell 
necrosis will be discussed.Finally possible modifications of this 
hypothesis and resulting ideas for future treatment strategies 
will be considered. 
The 'normal' host. 
Chronic HBV infection is characterized by a broad range of 
outcomes,which are thought to reflect differences in the cellular 
immune response of the host to HBV-infected hepatocytes (11). 
According to the classical hypothesis the hepatitis B virus is 
not cytopathic; liver cell necrosis is attributed to dual 
recognition of HBV and HLA antigens on the liver cell membrane by 
cytotoxic T-cells (figure 3).Treatment for this group of patients 
should be aimed at clearance of HBV. 
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HBV replication in infected liver cells Liver cell necrosis 
Liver cell membrane expression ..... T-een mediated cytotoxicity 
HBV antigens I HLA antigens 
fig 3.Mechanism of liver cell necrosis according to the classical 
hypothesis. 
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The immune-compromised host. 
Infection with the human immunodeficiency virus leads primarily 
to destruction of T-helper cells.Levels of HBV replication are 
higher in HIV-infected patients than in HBsAg-positive HIV 
antibody-negative patients.Liver lesions in the former often 
lack both necrosis and inflammatory infiltrates compared to those 
in HIV antibody-negative,HBsAg-positive patients (12). 
In HBsAg-positive renal transplant recipients reactivation of 
viral replication occurs during immunosuppressive therapy.In 
addition liver histology shows progressive fibrosis without much 
evidence of liver cell necrosis and minimal signs of 
inflammation.Compared to HBsAg-negative renal transplant 
recipients,survival is shorter (13). 
In HBsAg-positive liver transplant recipients,a mild clinical, 
biochemical and morphological -hepatitis occurs within three 
months of liver transplantation.This hepatitis coincides with 
cytoplasmic expression of HBcAg in the liver biopsy.HBV infection 
of the graft can be associated with rapid (within one year) 
development of cirrhosis in the graft.Although adequate 
immunosuppression prevents allograft rejection,rapidly 
progressive liver damage does occur in spite of immunologic 
incompetence (14,15). 
Other factors,in particular virus-induced antibody,also play a 
role in liver cell necrosis since HBV infection in patients with 
congenital agammaglobulinaemia often has a rapidly progressive 
course.This observation suggests that virus-induced antibody 
plays a role in limiting liver cell destruction (16). 
Treatment of immune-compromised patients should be aimed at 
decreasing the level of viral replication since it is unlikely 
that clearance of HBV is an attainable goal in these patients. 
Immune complex-mediated disease. 
In patients with HBV-associated periarteritis nodosa or glomerulo 
-nephritis,progressive extrahepatic damage may be associated with 
mild liver disease.The extrahepatic lesions are due to immune 
complex deposits in vessel walls or the kidney;apparently liver 
damage in these patients is not immune complex-mediated (17). 
Treatment for this group of patients should be aimed at clearance 
of the immune complexes,either by decreasing the production or 
increasing the rate of elimination of the immune complexes. 
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A modification of the classical hypothesis for HBV-induced liver 
cell necrosis. 
There are several important findings that cannot be explained by 
the classical hypothesis for HBV-induced liver cell necrosis,for 
instance the discrepancy between high levels of viral replication 
and the absence of liver damage in healthy carriers.Therefore it 
has been suggested that excess production of HBeAg and HBsAg 
impairs the cellular immune response to clear HBV-infected 
hepatocytes (18).The first modification of the classical 
hypothesis therefore is to include a regulatory role for HBV-
induced antigens in T cell-mediated immune mechanisms (fig 4.) 
Other unexplained findings are progressive HBV-induced liver 
damage in liver and renal transplant recipients with adequate 
suppression ofT cell-mediated cytotoxicity (no graft rejection). 
In addition,in our study the density and penetration of the 
inflammatory infiltrate in the livers of patients receiving 
exogenous alpha-interferon remained stable or decreased,even in 
the absence of HBe-seroconversion. 
Because of these unexplained findings we propose an additional 
modification of the classical hypothesis:in addition to T-cell-
mediated cytotoxicity we postulate a direct HBV replication-
associated cytopathic effect.Furthermore,cytokines that are 
evoked by the infection are presumed to modulate the disease 
process at various points,for instance virus replication may be 
suppressed.The progressive liver disease in transplant recipients 
can then be explained as follows:cyclosporin-A selectively 
inhibits cytokine production,both the absence of cytokines and 
the presence of steroids enhance HBV replication and direct 
cytopathic effects.The proposal of a direct replication-
associated cytopathic effect is supported by in vitro findings: 
cytopathic effects of HBV have been found in vitro in transfected 
hep-g2 cells with high cytoplasmic expression of HBcAg (19).In 
patients treated with alpha-interferon liver histology improves, 
which could support the theory of a protective role of cytokines 
like alpha-interferon <fig.S). 
In summary the mechanism by which HBV causes liver disease in the 
'normal'host is related to the cytotoxic T-cell response on liver 
cells expressing HBV and HLA antigens.The T-cell response may be 
modified by HBV antigens.Especially in immune-compromised hosts 
with high levels of viral replication the presence of a direct 
replication-associated cytopathic effect is likely to exist.The 
selective inhibition of cytokine production by cyclosporin-A in 
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HBV replication in infected liver cells Liver cell necrosis 
serum HBV antigens 
Liver cell membrane expression T-cell mediated cytotoxicity 
HBV antigens J HLA antigens 
fig 4.Mechanism of liver cell necrosis:T-cell-mediated 
cytotoxicity is regulated by the presence of serum HBV-
antigens. 
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fig S.A new hypothesis for the pathobiology of hepatitis B virus 
replication. 
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liver transplant recipients in combination with improvement in 
liver histology in patients receiving exogenous alpha-interferon 
suggests a protective role for cytokines. 
Future treatment strategies. 
Treatment aims. 
Treatment strategies for the 'normal' host should aim toward loss 
of active viral replication (HBe-seroconversion>,preferably 
followed by HBsAg seroconversion.In the immune-compromised host 
clearance of HBV is not an attainable goal but if our hypothesis 
is valid,a substantial decrease in the level of viral replication 
will result in a decrease in liver cell necrosis.Treatment of 
patients with immune complex-mediated diseases should be aimed at 
clearance of the immune complexes,by either decreasing the 
production or increasing the rate of elimination of the immune 
complexes. 
Nucleoside analogues. 
The principal action of nucleoside analogues is inhibition of 
viral replication.In theory they are excellent candidates for 
treatment of chronic hepatitis type B especially in immune-
compromised patients.A profile of the nucleoside analogue needed 
for new treatment strategies encompasses the following elements: 
inhibition of viral DNA-polymerase/reverse transcriptase activity 
and HBV-DNA synthesis,low toxicity with a view to long-term 
administration,no immunosuppressive effects and oral route of 
administration.This ideal nucleoside analogue is not available 
yet.The most promising developments in this field are drug-
targeting and inhibition of reverse transcription. 
Drug-targeting. 
Intramuscular ARA-AMP inhibits approximately 70 % of DNA-
polymerase activity and HBV-DNA.The use of the drug is limited by 
dose-related toxicity.The toxicity problem might possibly be 
solved by creating conjugates of carrier molecules and ARA-AMP. 
The use of conjugated molecules might make it possible to target 
the drug almost exclusively to the liver,with minimal systemic 
toxicity (20).The use of ARA-A conjugated to lactosaminated 
albumin, a neoglycoprotein which specifically penetrates 
hepatocytes,looks particularly promising in this respect (21). 
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Inhibition of reverse transcription. 
Ongoing extensive research on active drugs against the human 
immunodeficiency virus should produce a number of reverse 
transcriptase inhibitors.In vitro the triphosphate derivative of 
the reverse transcriptase inhibitor 3'-azido-3'deoxythymidine 
(zidovudineR) inhibits hepatitis B DNA-polymerase activity 
<22).In a pilot study zidovudine (4 x 200 mg daily) was shown to 
inhibit DNA-polymerase activity and decrease HBV-DNA.This drug is 
now being further evaluated in a dose-response study (23). 
Initial inhibition of DNA-polymerase activity did not exceed 
SO%.This incomplete inhibition and the expected toxicity during 
long-term use imply that single drug therapy with zidovudine is 
unlikely to be of great benefit.However it is the first oral 
reverse transcriptase inhibitor available that is active against 
HBV. 
Immunomodulatory therapy. 
Cytokines. 
Alpha-interferon inhibits 90 % of DNA-polymerase activity after 
one week and can promote clearance of HBsAg; this effect has not 
been reproduced by any other drug.In addition liver histology 
improves.Therefore exogenous administration of alpha-interferon 
appears to be a rational approach for the 'normal' host.Treatment 
strategies based on short 4-week courses of alpha-interferon in 
order to induce lower levels of viral replication before long-
term interferon therapy starts look of interest. 
A theoretical reason for concern is the development of 
neutralizing interferon antibodies during recombinant alpha-
interferon therapy.The antibody renders recombinant interferon 
ineffective,which could imply that preparations consisting of 
several different interferon subtypes may be preferred in the 
future (24).However in more recent studies anti-alpha interferon 
antibodies developed in one out of every ten patients without 
correlation with the outcome of therapy (25). 
Interleukin-2 therapy inhibits DNA-polymerase activity although 
pilot studies have produced contradictory results (26,27,28). 
Recently several cytokines including tumour necrosis factor and 
interleukins 1 and 2 were found to act in vitro synergistically 
with interferon (29).A serious dilemma at present is the choice 
of strategies worthy of further evaluation,because a clear 
insight into the interactions between the different cytokines is 
as yet lacking.A safe approach would be to use alpha-interferon 
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as a basic therapeutic regimen and to compare all other 
strategies with alpha-interferon. 
Monoclonal antibodies. 
The use of monoclonal antibodies for treatment of chronic viral 
infections in man is becoming a reality.Monoclonal anti-HBs can 
stop HBV replication in chimpanzees,probably by limiting the 
spread of the infection C30).In some liver transplant recipients 
large quantities of polyclonal anti-HBs can prevent reinfection 
of the graft liver (31). Patients with congenital 
agammaglobulinaemia and chronic HBV infection are now being 
treated successfully with repeated high dosages of murine 
monoclonal anti-HBs C32>.In theory administration of human 
monoclonal antibodies to patients with chronic HBV infection to 
reduce the initial virus load- before initiation of long-term 
interferon therapy seems an attractive option,especially because 
the result of antiviral therapy is related to pre-treatment 
levels of viral replication. 
Anti-idiotype antibodies. 
Cytotoxic T-cells are directed against viral antigens (HBcAg, 
HBeAg) on the liver cell membrane as well as HLA antigens.The 
anti-HBc antibody may mask expression of HBcAg,thereby preventing 
clearance of virus-infected hepatocytes.In theory down-regulation 
of anti-HBc production,by anti-idiotype antibodies,increases 
exposure of infected hepatocytes to the immune system and may 
enhance clearance of infected hepatocytes (33).This strategy is 
not aimed at inhibition of viral replication but depends entirely 
on the integrity of the patient's immune system for eradication 
of the virus. 
Plasmapheresis and nucleoside anlogues. 
Treatment of patients with immune complex-mediated diseases 
should be aimed at clearance of the immune complexes either by 
decreasing the production or increasing the rate of elimination 
of the immune complexes.The former approach has been shown to be 
successful in glomerulonephritis caused by chronic HBV infection. 
In these patients a 4-month course of alpha-interferon can induce 
clinical,biochemical and histologic remission (34,35>.The 
combination of decreasing the production and increasing the rate 
of elimination of immune complexes has been successful in 
patients with hepatitis B-associated periarteritis nodosa. 
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Promising results were obtained with the combination of short 
term corticosteroids,repeated courses of ARA-A and plasmapheresis 
(36) .This therapy is now being compared with standard 
immunosuppressive therapy for periarteritis nodosa in a 
randomized controlled trial. 
Conclusions. 
The therapeutic results of combination therapy have not come up 
to expectations compared to the results obtained with alpha-
interferon alone.On the basis of the results of our studies and 
recent data from literature we developed a new hypothesis for 
HBV-induced liver damage.The central premise of this hypothesis 
is the co-existence of the replication-associated cytopathic 
effect and T cell-mediated cytotoxicity modulated by cytokines. 
Treatment strategies can be directed toward suppression of virus 
replication,viral clearance or clearance of virus-related immune 
complexes.In 'normal' hosts alpha-interferon can promote HBsAg 
clearance and is now considered the standard regimen for chronic 
hepatitis B.Improvement of treatment results has to be obtained 
by repeated courses of alpha-interferon or combination therapy 
with nucleoside analogues or other cytokines.Immune-compromised 
patients are likely to benefit from a substantial decrease in the 
level of viral replication either by long term nucleoside 
analogues or antibody therapy.For patients with immune complex-
mediated disease treatment should be aimed at clearance of the 
immune complexes either by decreasing the production or 
increasing the rate of elimination of the immune complexes; 
alpha-interferon alone or the combination of plasmapheresis and 
corticosteroids followed by a nucleoside analogue may be 
beneficial in these cases. 
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Summary. 
The number of patients with chronic hepatitis B virus <HBV) 
infection worldwide is estimated to be 200 million, 25 % of whom 
will eventually die of an HBV-related disease.Elimination of the 
hepatitis B virus is now considered the key to effective 
treatment of chronic HBV infection.In this thesis clinical 
studies on antiviral therapy for patients with chronic HBV 
infection are described.The studies were designed to evaluate the 
inhibitory effect on HBV replication of acyclovir,descyclovir and 
alpha-interferon,alone or in combination. 
A review of the history of the hepatitis B virus and the 
discovery of virus-related antigens and antibodies is presented 
in chapter l.The natural histories of the clinical,biochemical 
and histological sequelae of HBV infection are discussed.Goals 
and possible strategies for therapy are outlined.The aim of the 
studies is defined. 
In chapter 2 the effects of acyclovir,adenine arabinoside,alpha-
interferon or corticosteroid withdrawal as single therapeutic 
modality for chronic HBV infection are reviewed.We compared the 
loss of active viral replication achieved.Meta-analysis of the 
individual studies showed that therapy with alpha-interferon is 
superior to both adenine arabinoside and acyclovir,as far as 
persistent suppression of active HBV replication is concerned. 
In chapter 3 the effects of oral and intravenous acyclovir and 
descyclovir on markers of HBV replication are described.Oral 
acyclovir appears to be ineffective in chronic HBV infection, 
whereas high-dose intravenous acyclovir transiently inhibits HBV 
replication.Descyclovir has no significant inhibitory effect on 
HBV replication.Single drug therapy with acyclovir or descyclovir 
is not a valid option for chronic HBV infection. 
A pilot study on intravenous acyclovir,alpha-interferon and a 
combination of the two drugs (chapter 4> indicated enhancement 
of the antiviral effect of alpha-interferon by acyclovir,compared 
to either drug alone. 
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In a randomized controlled study <chapter 5> a four-month course 
of a combination of alpha-interferon and descyclovir was compared 
with no therapy.Combination therapy was shown to inhibit viral 
replication.Loss of active viral replication (HBe-seroconversion) 
was significantly higher in treated patients (40 per cent) 
compared to untreated patients (0 per cent).Patients with low 
levels of viral replication before treatment responded to therapy 
with loss of active viral replication;in others only a transient 
inhibitory effect on HBV replication was seen. 
The long-term efficacy,incidence of viral reactivation and 
improvement in liver disease for patients treated with 
intravenous acyclovir,alpha-interferon or a combination of the 
two drugs were evaluated <chapter 6).Results indicate persistent 
loss of active viral replication in 40 % of patients treated with 
combination therapy compared to 30 % on alpha-interferon therapy, 
18 % on acyclovir therapy and 0 % without treatment.Clinical 
improvement and prolonged normalization of liver tests were found 
for all patients who exhibited loss of active HBV replication. 
In chapter 7, long-term follow-up studies, with emphasis on 
biochemical and histological improvement of the liver disease,are 
reported;all patients participated in a randomized controlled 
study on alpha-interferon and descyclovir.After 16 weeks of 
therapy,there were significant differences in the number of 
treated patients who became HBV-DNA and DNA-polymerase negative 
compared to the untreated patients.After one year of observation, 
the significant difference in the number of HBeAg-negative 
patients observed at 32 weeks persisted,but the differences in 
serum HBV-DNA and DNA-polymerase activity observed at 16 weeks 
had disappeared due to reactivation in treated patients and 
spontaneous loss of these markers in untreated patients.Absence 
of HBeAg,as indicated by a quantatative assay,represents a 
reliable marker of therapeutic success: patients who lost this 
marker of active viral replication did not exhibit reactivation. 
Patients who became HBeAg negative usually showed normalization 
of liver function tests.In treated patients histology improved 
compared to that found for untreated control patients,i.e.there 
was a significant decrease in density and penetration of the 
inflammatory infiltrate in the liver biopsy.In all cases 
disappearance of HBeAg and HBV-DNA from the blood was 
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accompanied by the disappearance of HBcAg in the liver. 
In chapter 8 beta-2 microglobulin levels in the patients with 
chronic HBV infection participating in our study on alpha-
interferon and descyclovir combination therapy were assessed to 
determine whether the beta-2 microglobulin level is prognostic 
for HBe-seroconversion.Pretreatment elevation of beta-2 
microglobulin was observed in 39 % of patients.Significant 
differences in the mean beta-2 microglobulin levels between 
treated patients and untreated controls were observed after 4 
and 8 weeks of treatment.Levels in control patients remained 
stable.The outcome of antiviral therapy in our patients was not 
dependent on beta-2 microglobulin levels measured before or 
during antiviral combination therapy. 
The treatment of a young patient with an incapacitating nephrotic 
syndrome and membranous glomerulonephritis,possibly related to 
active HBV replication,is discussed (chapter 9).Signs of liver 
disease were minimal:serum aminotransferases were normal and 
liver histology showed mild chronic persistent hepatitis with 
HBsAg,HBeAg and HBcAg positivity.In the kidney deposits of 
HBeAg,HBcAg,IgG,c3 and clq were observed.After 8 weeks of 
antiviral combination therapy,replication ceased and urinary 
protein loss decreased.One year after treatment the boy was 
asymptomatic.No HBV markers could be detected in the kidney 
although low grade membranous glomerulonephritis persisted.It 
appears that antiviral therapy can be beneficial for patients 
with active viral replication and deposits of HBc,HBe immune 
complexes in the kidney,even in the absence of active liver 
disease. 
New approaches to and possible future developments in antiviral 
therapy are also considered (chapter lO).Meta-analysis of 27 
randomized controlled trials showed that the therapeutic results 
with combination therapy have not come up to expectations 
compared to the results obtained with alpha-interferon alone. 
On the basis of the results of our studies and recent data from 
literature we developed a new hypothesis for HBV-induced liver 
damage,aimed at a differential appoach to antiviral treatment 
dependent upon specific circumstances.The central premise of this 
hypothesis is the co-existence of the replication-associated 
cytopathic effect and T-cell mediated cytotoxicity. 
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Treatment strategies can be directed toward suppression of virus 
replication,viral clearance or clearance of virus-related immune 
complexes.In 'normal' hosts alpha-interferon can promote HBsAg 
clearance and is now considered the standard regimen for chronic 
hepatitis B.Improvement of treatment results has to be obtained 
by repeated courses of alpha-interferon or combination therapy 
with nucleoside analogues or other cytokines.Immune compromised 
patients are likely to benefit from a substantial decrease in the 
level of viral replication either by long term nucleoside 
analogues or antibody therapy.In patients with immune complex-
mediated disease treatment should be aimed at clearance of the 
immune complexes either by decreasing the production or 
increasing the rate of elimination of the immune complexes; 
alpha-interferon alone or in combination with a nucleoside 
analogue and plasmapheresis may be beneficial in selected cases. 
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Samenvatting. 
Het totaal aantal patienten met een chronische hepatitis B virus 
infectie op de wereld wordt geschat op 200 miljoen,25 % van hen 
zal uiteindelijk overlijden als direct gevolg van de infectie of 
een eraan gerelateerde complicatie.Klaring van het hepatitis B 
virus CHBV) is daarom de kern van een effectieve behandeling van 
een chronische HBV infectie.In dit proefschrift worden klinische 
studies over antivirale therapie bij patienten met een chronische 
HBV infectie beschreven.De studies werden uitgevoerd om inzicht 
te krijgen in het effect op virale replicatie van acyclovir, 
descyclovir en alta-interferon als monotherapie of in combinatie. 
Het inleidend hoofdstuk 1 bevat een overzicht van de geschiedenis 
van het hepatitis B virus en de ontdekking van de aan het virus 
gerelateerde antigenen en antillchamen.Het natuurlijk beloop van 
de klinische,biochemische en histologische gevolgen van een HBV 
infectie wordt besproken.Aan de hand van de replicatie cyclus 
van het virus wordt nader ingegaan op mogelijke ingangen voor 
antivirale therapie.Het doel van onze studies wordt gedefinieerd. 
In hoofdstuk 2 wordt een overzicht gegeven van de werkings-
mechanismen en resultaten van antivirale behandeling met 
acyclovir, adenine arabinoside, alta-interferon en cortico-
steroiden toegepast als monotherapie.Door middel van meta-analyse 
van de individuele studies wordt het verlies van actieve virale 
replicatie vergeleken.Blijvende onderdrukking van virus 
replicatie wordt met alfa-interferon vaker bereikt dan met 
adenine arabinoside of acyclovir. 
In hoofdstuk 3 worden de resultaten van acyclovir (oraal en 
intraveneus) op het niveau van HBV replicatie beschreven.Oraal 
acyclovir lijkt niet effectief bij de onderdrukking van HBV 
replicatie, terwijl hoge dosis intraveneus acyclovir HBV 
replicatie tijdelijk kan remmen.Descyclovir in lage dosering 
heeft geen significant remmend effect op HBV replicatie.Mono-
therapie met acyclovir of descyclovir als behandeling van een 
chronische HBV infectie lijkt niet zinvol. 
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In hoofdstuk 4 worden klinische studies beschreven met intra-
veneus acyclovir,alfa-interferon of de combinatie van deze twee 
geneesmiddelen.De resultaten wijzen op een versterking van het 
antivirale effect van alta-interferon door acyclovir in verge-
lijking met het effect van de afzonderlijke geneesmiddelen 
toegepast als monotherapie. 
In hoofdstuk 5 worden de resultaten beschreven van een gerando-
miseerd gecontroleerd onderzoek naar de effectiviteit van vier 
maanden behandeling met alfa-interferon en descyclovir.Het 
verlies van actieve virale replicatie CHBeAg seroconversie) was 
significant hoger in behandelde patienten (40 procent) in 
vergelijking met onbehandelde patienten (0 procent).Patienten die 
een laag niveau van virale replicatie hadden bij aanvang van de 
studie reageerden op therapie met verlies van actieve virale 
replicatie;anderen toonden alleen tijdens therapie een remming 
van de HBV replicatie. 
Hoofdstuk 6 beschrijft de effectiviteit op lange termijn,het 
voorkomen van reactivatie van de virus infectie en de verbetering 
van de leverziekte bij patienten behandeld met intraveneus 
acyclovir, alfa-interferon of de combinatie van deze twee 
geneesmiddelen.De resultaten wijzen op een blijvend verlies van 
actieve virale replicatie in 40 % van de patienten behandeld met 
combinatie therapie in vergelijking tot 30 % met alfa-interferon, 
18 % met acyclovir en 0 % zonder behandeling.Klinische verbete-
ring en blijvende normalisering van de leverfunties werd 
waargenomen bij alle patienten die actieve HBV replicatie 
verloren. 
In hoofdstuk 7 wordt een lange termijn vervolgonderzoek 
beschreven, met nadruk op biochemische en histologische 
verbetering van de leverziekte,bij patienten die deelnamen aan 
een gerandomiseerd gecontroleerd onderzoek over de combinatie 
alfa-interferon en descyclovir.Na 16 weken therapie bestaan er 
significante verschillen tussen het aantal patienten dat HBV-DNA 
en DNA-polymerase verliest in de behandelde groep in vergelijking 
met de onbehandelde controle groep.Na 32 weken is dit verschil 
ook significant voor HBeAg.Na een jaar observatie blijft het 
verschil in het aantal HBeAg negatieve patienten significant, 
maar de verschillen in HBV-DNA en DNA-polymerase activiteit zoals 
die op 16 weken bestaan verdwijnen als gevolg van reactivatie in 
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behandelde patienten en het natuurlijk beloop in onbehandelde 
patienten.Afwezigheid van HBeAg gemeten in een kwantitatieve test 
is een betrouwbare maat voor therapeutisch succes: bij patienten 
die deze parameter van actieve virale replicatie verloren werden 
geen reactivaties gezien.Tevens toonden zij verbetering en 
meestal normalisering van leverfuncties.Bij alle behandelde 
patienten toonde de lever histologie verbetering in vergelijking 
met onbehandelde patienten: een significante afname van de 
dichtheid en penetratie van het portaal onstekings infiltraat in 
de biopsie.Bij patienten die HBeAg en HBV-DNA uit het bloed 
verloren werd geen HBcAg meer in de lever gevonden. 
In hoofdstuk 8 worden de resultaten van het onderzoek naar serum 
spiegels van beta-2 microglobuline bij patienten met een 
chronische HBV infectie besproken.Alle patienten namen deel aan 
ons gerandomiseerd gecontroleerd onderzoek naar de effectiviteit 
van alfa-interferon en descyclovir.Onderzocht werden beta-2 
microglobuline spiegels voor en tijdens antivirale therapie om 
uit te maken of beta-2 microglobuline een prognostische waarde 
heeft ten aanzien van een gunstige therapeutische respons op 
therapie.Voor aanvang van therapie werd een verhoogd serum beta-2 
microglobuline gevonden bij 39 % van de patienten.Significante 
verschillen in beta-2 microglobuline ontstonden tijdens de 
behandeling tussen behandelde en onbehandelde patienten na 4 en 8 
weken behandeling.Het niveau bij onbehandelde controle patienten 
bleef stabiel.Het eindresultaat van de antivirale therapie was 
bij onze patienten niet afhankelijk van het niveau van beta-2 
microglobuline gemeten voor of tijdens de antivirale therapie. 
In hoofdstuk 9 wordt de behandeling van een jonge patient met een 
invaliderend nefrotisch syndroom en membraneuze glomerulo-
nephritis, mogelijk gerelateerd aan actieve HBV replicatie, 
besproken.Bij deze patient waren de tekenen van een actieve 
leverziekte minimaal: er waren geen biochemische tekenen van 
hepatitis,terwijl de lever histologie een milde chronisch 
persisterende hepatitis toonde met de aanwezigheid van HBsAg, 
HBeAg en HBcAg.In de nierbiopsie werden deposities van HBeAg, 
HBcAg,IgG,c3,clq aangetoond.Na 8 weken antivirale therapie nam 
de virale replicatie af, gevolgd door een afname van het eiwit 
verlies in de urine.Een jaar na behandeling was de patient 
klachten vrij.In denier konden geen HBV-antigenen meer worden 
aangetoond,er persisteerde echter een milde membraneuze 
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glomerulonephritis.Antivirale therapie kan van waarde zijn bij 
patienten met actieve HBV replicatie en deposities van HBc,HBe 
immuun-complexen in de nier,zelfs als er geen actieve leverziekte 
aanwezig is. 
In hoofdstuk 10 worden nieuwe benaderingen en de mogelijke 
toekomstige ontwikkelingen in antivirale therapie besproken.Meta-
analyse van 27 gerandomiseerde gecontroleerde onderzoeken toonde 
aan dat antivirale combinatie therapie misschien een klein 
additioneel effect heeft,maar niet heeft kunnen voldoen aan de 
hoog gespannen verwachtingen ten opzichte van therapie met alta-
interferon alleen. 
Uitgaande van de nieuwe gegevens voortgekomen uit onze studies en 
uit de literatuur,wordt een model ontwikkeld gericht op een 
gedifferentieerde aanpak voor antivirale therapie in verschil-
lende groepen patienten.Vooral in de immuun gecompromitteerde 
patienten met zeer hoge virale replicatie <HBV positieve 
transplantatie patienten, anti-HIV positieve patienten) is het 
waarschijnlijk, dat naast de door de cytotoxische T-cel 
veroorzaakte schade er sprake is van een HBV-replicatie 
geassocieerd cytopathogeen effect. 
Antivirale therapie kan zich richten op volledige virus klaring 
(HBsAg seroconversie), verlagen van het niveau van virus 
replicatie of het omlaag brengen van de met het virus 
geassocieerde immuuncomplexen.Bij de 'normale' gastheer bestaat 
antivirale therapie uit alpha-interferon,temeer daar hierdoor 
HBsAg klaring versneld wordt.Verbetering van de behandelings 
resultaten moet komen van herhaalde interferon kuren of de 
combinatie met andere cytokines of nucleoside analogen.Het model 
ondersteunt de causale rol van antivirale therapie bij immuun 
gecompromitteerde patienten:remming van virale replicatie om 
progressieve lever schade te voorkomen.Bij patienten met door 
HBV immuun complexen veroorzaakte ziekten kan alta-interferon of 
een combinatie van een nucleoside analoog met plasmaferese nuttig 
zijn.Toekomstige ontwikkelingen in antivirale therapie zullen 
afhangen van de identificatie van nieuwe aangrijpingspunten voor 
antivirale therapie (remming van 'reverse transcriptase' activi-
teit, monoclonale of anti-idiotype antilichamen), verbeterde 
toedienings vormen voor bestaande geneesmiddelen door koppeling 
aan specifieke drager eiwitten of de ontwikkeling van nieuwe 
antivirale geneesmiddelen. 
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van Buuren dank ik voor hun morele steun,niet alleen tijdens de 
promotie.De samenwerking met de collegae van het Academisch 
Medisch Centrum Amsterdam <dr.R.A.F.M.Chamuleau, dr.H.W.Reesink, 
dr.R.Grijm),het Sint Fransiscus Gasthuis (dr.M de Jong, Mw.J den 
Ouden-Muller) en het Sofia Kinderziekenhuis (dr.A.J.van der 
Heijden, dr.E.D.Wolff) verliep steeds plezierig.Administratieve 
contacten tussen de onderzoeks centra werden onderhouden door 
Mw.M.Bakker-Bendik en Mw.R van de Meer.De serologische 
bepalingen betreffende hepatitis B werden verricht in het 
virologisch laboratorium door Mw.Y.A.M.Weber en dhr.J.Kruining. 
Het beheer van de serum bank en de acyclovir spiegel bepalingen 
werden gedaan op het laboratorium Inwendige Geneeskunde II door 
mw.G.J.Voortman en dhr.A.J.H.de Boer.Alle histologie preparaten 
werden herbeoordeeld door dr.F.J.W.ten Kate,afdeling Klinische 
Pathologie,Erasmus Universiteit Rotterdam.De beta-2 microglobu-
line bepalingen werden verricht op de afdeling haematologie door 
mw.N.Vink-Wendels en dhr.C.A.de Leeuw onder leiding van 
dr.J.Lindemans.Bij computer problemen kwam er steeds goede raad 
van dhr.J.Boot,afdeling Inwendige Geneeskunde II.Statistisch 
advies werd verkregen van de afdeling Biostatistica van de 
Erasmus Universiteit Rotterdam dr.ir.P.I.M.Schmitz,ir.W.C.J.Hop, 
dr.Th Stijnen.De tekeningen en foto's in dit proefschrift werden 
vervaardigd door het Audiovisueel Centrum van de Erasmus 
Universiteit Rotterdam.De gepubliceerde manuscripten werden 
steeds met zorg bewerkt door Mw.M.A.A.van Noord-Haubrich en 
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Mw.W.Beukman.De engelse tekst werd met zorg gecorrigeerd door 
Mw.G.P.Bieger-Smith. 
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Curriculum vitae. 
De auteur van dit proefschrift werd geboren in 1957 te Rotterdam. 
Hij bezocht de Caland Scholengemeenschap te Rotterdam,alwaar hij 
in 1975 het Atheneum-B diploma behaalde.In 1975 werd aangevangen 
met de studie economie aan de Erasmus Universiteit te Rotterdam. 
Januari 1978 werd het kandidaatsexamen algemene economie behaald. 
In september 1978 werd gestart met de studie geneeskunde aan de 
Erasmus Universiteit te Rotterdam.Gedurende deze jaren was hij 
actief als wedstrijdroeier en wedstrijdcoach bij de ARSR SKADI. 
Januari 1985 werd het artsexamen behaald.Aansluitend werkte hij 
op de afdeling Inwendige Geneeskunde II (hoofd Prof.J.H.P.Wilson) 
van het Academisch Ziekenhuis Rotterdam Dijkzigt;hier werd onder 
leiding van Prof.dr.S.W.Schalm de basis gelegd voor dit 
proefschrift.In april 1987 werd begonnen met de opleiding tot 
internist in het Academisch Ziekenhuis Rotterdam Dijkzigt 
(opleider Prof.dr.J.C.Birkenhager).Hij is gehuwd met Anne Marijke 
Breimer,zij hebben een zoon Auke Jeroen. 

